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Foreword 
 
The evaluation of research and doctoral training is being carried out in the years 2010–2012 and will end in 
2012. The steering group appointed by the Rector in January 2010 set the conditions for participating in 
the evaluation and prepared the Terms of Reference to present the evaluation procedure and criteria. The 
publications and other scientific activities included in the evaluation covered the years 2005–2010. 
The participating unit in the evaluation was defined as a Researcher Community (RC). To obtain a 
critical mass with university-level impact, the number of members was set to range from 20 to 120. The 
RCs were required to contain researchers in all stages of their research career, from doctoral students to 
principal investigators (PIs). All in all, 136 Researcher Communities participated in this voluntary 
evaluation, 5857 persons in total, of whom 1131 were principal investigators. PIs were allowed to 
participate in two communities in certain cases, and 72 of them used this opportunity and participated in 
two RCs. 
This evaluation enabled researchers to define RCs from the “bottom up” and across disciplines. The aim 
of the evaluation was not to assess individual performance but a community with shared aims and 
researcher-training activities. The RCs were able to choose among five different categories that 
characterised the status and main aims of their research. The steering group considered the process of 
applying to participate in the evaluation to be important, which lead to the establishment of these 
categories. In addition, providing a service for the RCs to enable them to benchmark their research at the 
global level was a main goal of the evaluation. 
The data for the evaluation consisted of the RCs’ answers to evaluation questions on supplied e-forms 
and a compilation extracted from the TUHAT – Research Information System (RIS) on 12 April 2011. The 
compilation covered scientific and other publications as well as certain areas of scientific activities. During 
the process, the RCs were asked to check the list of publications and other scientific activities and make 
corrections if needed. These TUHAT compilations are public and available on the evaluation project sites 
of each RC in the TUHAT-RIS. 
In addition to the e-form and TUHAT compilation, University of Leiden (CWTS) carried out bibliometric 
analyses from the articles included in the Web of Science (WoS). This was done on University and RC 
levels. In cases where the publication forums of the RC were clearly not represented by the WoS data, the 
Library of the University of Helsinki conducted a separate analysis of the publications. This was done for 
66 RCs representing the humanities and social sciences. 
The evaluation office also carried out an enquiry targeted to the supervisors and PhD candidates about 
the organisation of doctoral studies at the University of Helsinki. This and other documents describing the 
University and the Finnish higher education system were provided to the panellists. 
The panel feedback for each RC is unique and presented as an entity. The first collective evaluation 
reports available for the whole panel were prepared in July–August 2011. The reports were accessible to all 
panel members via the electronic evaluation platform in August. Scoring from 1 to 5 was used to 
complement written feedback in association with evaluation questions 1–4 (scientific focus and quality, 
doctoral training, societal impact, cooperation) and in addition to the category evaluating the fitness for 
participation in the evaluation. Panellists used the international level as a point of comparison in the 
evaluation. Scoring was not expected to go along with a preset deviation. 
Each of the draft reports were discussed and dealt with by the panel in meetings in Helsinki (from 11 
September to 13 September or from 18 September to 20 September 2011). In these meetings the panels 
also examined the deviations among the scores and finalised the draft reports together. 
The current RC-specific report deals shortly with the background of the evaluation and the terms of 
participation. The main evaluation feedback is provided in the evaluation report, organised according to 
the evaluation questions. The original material provided by the RCs for the panellists has been attached to 
these documents. 
 
 
 
 
 
 
 
 
 
On behalf of the evaluation steering group and office, I sincerely wish to thank you warmly for your 
participation in this evaluation. The effort you made in submitting the data to TUHAT-RIS is gratefully 
acknowledged by the University. We wish that you find this panel feedback useful in many ways. The 
bibliometric profiles may open a new view on your publication forums and provide a perspective for 
discussion on your choice of forums. We especially hope that this evaluation report will help you in setting 
the future goals of your research. 
 
Johanna Björkroth 
Vice-Rector 
Chair of the Steering Group of the Evaluation 
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Steering group, nominated by the Rector of the University, was responsible for the  
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between February 2010 and March 2012. 
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Vice-Rector, professor Johanna Björkroth 
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Panel members 
CHAIR 
Professor Jan-Otto Carlsson 
Materials science in chemistry and physics, nanotechnology, inorganic 
chemistry 
Uppsala University, Sweden 
 
VICE-CHAIR 
Professor Jan van Leeuwen 
Computer science, information technology 
University of Utrecht, the Netherlands 
 
Professor Caitlin Buck 
Probability and statistics, archeology, palaeoenvironmental science 
University of Sheffield, Great Britain 
 
Professor David Colton 
Mathematics, inverse problems of acoustic and electromagnetic scattering 
University of Delaware, USA 
 
Professor Jean-Pierre Eckmann 
Mathematics, dynamical systems, mathematical physics 
University of Geneva, Switzerland 
 
Professor Ritske Huismans 
Geosciences, geodynamics 
University of Bergen, Norway 
 
Professor Jukka Jurvelin 
Medical physics and engineering 
University of Eastern Finland 
 
Professor Lea Kauppi 
Environmental sciences, water research 
The Finnish Environment Institute, Finland 
 
Professor Riitta Keiski 
Chemical engineering, heterogeneous catalysis, environmental technology, 
mass and heat transfer processes 
University of Oulu, Finland 
 
Professor Mats Larsson 
Experimental molecular physics, chemical dynamics, molecular spectroscopy, 
astrobiology 
Stockholm University, Sweden 
 
Professor Holger Stark 
Medicinal, organic and pharmaceutical chemistry, pharmacology 
Johann Wolfgang Goethe Universität, Germany 
 
The panel, independently, evaluated all the submitted material and was responsible for the 
feedback of the RC-specific reports. The panel members were asked to confirm whether they had any 
conflict of interests with the RCs. If this was the case, the panel members disqualified themselves in 
discussion and report writing. 
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Added expertise to the evaluation was contributed by the members from the other panels. 
 
Experts from the Other Panels 
Professor Barbara Koch, from the Panel of Biological, Agricultural and Veterinary Sciences 
Professor Peter York, from the Panel of Medicine, Biomedicine and Health Sciences 
 
 
EVALUATION OFFICE 
Dr Seppo Saari, Doc., Senior Adviser in Evaluation, was responsible for the entire 
evaluation, its planning and implementation and acted as an Editor-in-chief of the 
reports. 
 
Dr Eeva Sievi, Doc., Adviser, was responsible for the registration and evaluation 
material compilations for the panellists. She worked in the evaluation office from 
August 2010 to July 2011. 
 
MSocSc Paula Ranne, Planning Officer, was responsible for organising the panel 
meetings and all the other practical issues like agreements and fees and editing a 
part the RC-specific reports. She worked in the evaluation office from March 2011 
to January 2012. 
 
Mr Antti Moilanen, Project Secretary, was responsible for editing the reports. He 
worked in the evaluation office from January 2012 to April 2012. 
 
TUHAT OFFICE 
Provision of the publication and other scientific activity data 
Mrs Aija Kaitera, Project Manager of TUHAT-RIS served the project ex officio 
providing the evaluation project with the updated information from TUHAT-RIS. 
The TUHAT office assisted in mapping the publications with CWTS/University of 
Leiden. 
 
MA Liisa Ekebom, Assisting Officer, served in TUHAT-RIS updating the 
publications for the evaluation. She also assisted the UH/Library analyses. 
 
BA Liisa Jäppinen, Assisting Officer, served in TUHAT-RIS updating the 
publications for the evaluation. 
 
HELSINKI UNIVERSITY LIBRARY 
Provision of the publication analyses 
Dr Maria Forsman, Chief Information Specialist in the Helsinki University Library, 
managed with her 10 colleagues the bibliometric analyses in humanities, social 
sciences and in other fields of sciences where CWTS analyses were not 
applicable. 
 
  
 
 
3 
 
 
Acronyms and abbreviations applied in the report 
 
External competitive funding 
AF – Academy of Finland 
TEKES - Finnish Funding Agency for Technology and Innovation  
EU - European Union 
ERC - European Research Council 
International and national foundations 
FP7/6 etc. /Framework Programmes/Funding of European Commission 
 
Evaluation marks 
Outstanding (5) 
Excellent  (4) 
Very Good  (3) 
Good  (2) 
Sufficient  (1) 
 
Abbreviations of Bibliometric Indicators 
P - Number of publications 
TCS – Total number of citations 
MCS - Number of citations per publication, excluding self-citations 
PNC - Percentage of uncited publications 
MNCS - Field-normalized number of citations per publication 
MNJS - Field-normalized average journal impact 
THCP10 - Field-normalized proportion highly cited publications (top 10%) 
INT_COV - Internal coverage, the average amount of references covered by the WoS 
WoS – Thomson Reuters Web of Science Databases 
 
Participation category 
Category 1. The research of the participating community represents the international cutting edge in its 
field. 
Category 2. The research of the participating community is of high quality, but the community in its 
present composition has yet to achieve strong international recognition or a clear break-through. 
Category 3. The research of the participating community is distinct from mainstream research, and the 
special features of the research tradition in the field must be considered in the evaluation. 
Category 4. The research of the participating community represents an innovative opening. 
Category 5. The research of the participating community has a highly significant societal impact. 
 
Research focus areas of the University of Helsinki 
Focus area 1: The basic structure, materials and natural resources of the physical world 
Focus area 2: The basic structure of life 
Focus area 3: The changing environment – clean water 
Focus area 4: The thinking and learning human being 
Focus area 5: Welfare and safety 
Focus area 6: Clinical research 
Focus area 7: Precise reasoning 
Focus area 8: Language and culture 
Focus area 9: Social justice 
Focus area 10: Globalisation and social change 
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1 Introduction to the Evaluation 
1.1 RC-specific evaluation reports 
The participants in the evaluation of research and doctoral training were Researcher Communities 
(hereafter referred to as the RC). The RC refers to the group of researchers who registered together in the 
evaluation of their research and doctoral training. Preconditions in forming RCs were stated in the 
Guidelines for the Participating Researcher Communities. The RCs defined themselves whether their 
compositions should be considered well-established or new. 
It is essential to emphasise that the evaluation combines both meta-evaluation1 and traditional 
research assessment exercise and its focus is both on the research outcomes and procedures associated 
with research and doctoral training. The approach to the evaluation is enhancement-led where self-
evaluation constituted the main information. The answers to the evaluation questions formed together 
with the information of publications and other scientific activities an entity that was to be reviewed as a 
whole. 
The present evaluation recognizes and justifies the diversity of research practices and publication 
traditions. Traditional Research Assessment Exercises do not necessarily value high quality research with 
low volumes or research distinct from mainstream research. It is challenging to expose the diversity of 
research to fair comparison. To understand the essence of different research practices and to do justice to 
their diversity was one of the main challenges of the present evaluation method. Understanding the 
divergent starting points of the RCs demanded sensitivity from the evaluators. 
1.2 Aims and objectives in the evaluation 
The aims of the evaluation are as follows: 
 to improve the level of research and doctoral training at the University of Helsinki and to raise 
their international profile in accordance with the University’s strategic policies. The improvement 
of doctoral training should be compared to the University’s policy.2 
 to enhance the research conducted at the University by taking into account the diversity, 
originality, multidisciplinary nature, success and field-specificity, 
 to recognize the conditions and prerequisites under which excellent, original and high-impact 
research is carried out, 
 to offer the academic community the opportunity to receive topical and versatile international 
peer feedback, 
 to better recognize the University’s research potential. 
 to exploit the University’s TUHAT research information system to enable transparency of 
publishing activities and in the production of reliable, comparable data. 
1.3 Evaluation method 
The evaluation can be considered as an enhancement-led evaluation. Instead of ranking, the main aim is to 
provide useful information for the enhancement of research and doctoral training of the participating RCs. 
The comparison should take into account each field of science and acknowledge their special character. 
                                                                
1 The panellists did not read research reports or abstracts but instead, they evaluated answers to the evaluation 
questions, tables and compilations of publications, other scientific activities, bibliometrics or comparable analyses. 
2
 Policies on doctoral degrees and other postgraduate degrees at the University of Helsinki.  
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The comparison produced information about the present status and factors that have lead to success. Also 
challenges in the operations and outcomes were recognized. 
The evaluation approach has been designed to recognize better the significance and specific nature of 
researcher communities and research areas in the multidisciplinary top-level university. Furthermore, one 
of the aims of the evaluation is to bring to light those evaluation aspects that differ from the prevalent 
ones. Thus the views of various fields of research can be described and research arising from various 
starting points understood better. The doctoral training is integrated into the evaluation as a natural 
component related to research. Operational processes of doctoral training are being examined in the 
evaluation. 
 
Five stages of the evaluation method were: 
1. Registration – Stage 1 
2. Self-evaluation – Stage 2 
3. TUHAT3 compilations on publications and other scientific activities4 
4. External evaluation 
5. Public reporting 
1.4 Implementation of the external evaluation 
Five Evaluation Panels 
Five evaluation panels consisted of independent, renowned and highly respected experts. The main 
domains of the panels are: 
1. biological, agricultural and veterinary sciences 
2. medicine, biomedicine and health sciences 
3. natural sciences 
4. humanities 
5. social sciences 
The University invited 10 renowned scientists to act as chairs or vice-chairs of the five panels based on 
the suggestions of faculties and independent institutes. Besides leading the work of the panel, an 
additional role of the chairs was to discuss with other panel chairs in order to adopt a broadly similar 
approach. The panel chairs and vice-chairs had a pre-meeting on 27 May 2011 in Amsterdam. 
The panel compositions were nominated by the Rector of the University 27 April 2011. The participating 
RCs suggested the panel members. The total number of panel members was 50. The reason for a smaller 
number of panellists as compared to the previous evaluations was the character of the evaluation as a 
meta-evaluation. The panellists did not read research reports or abstracts but instead, they evaluated 
answers to the evaluation questions, tables and compilations of publications, other scientific activities, 
bibliometrics and comparable analyses. 
 
The panel meetings were held in Helsinki: 
 On 11–13 September 2011: (1) biological, agricultural and veterinary sciences, (2) medicine, 
biomedicine and health sciences and (3) natural sciences.  
 On 18–20 September 2011: (4) humanities and (5) social sciences. 
  
                                                                
3 TUHAT (acronym) of Research Information System (RIS) of the University of Helsinki 
4 Supervision of thesis, prizes and awards, editorial work and peer reviews, participation in committees, boards and 
networks and public appearances. 
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1.5 Evaluation material 
The main material in the evaluation was the RCs’ self-evaluations that were qualitative in character and 
allowed the RCs to choose what was important to mention or emphasise and what was left unmentioned. 
The present evaluation is exceptional at least in the Finnish context because it is based on both the 
evaluation documentation (self-evaluation questions, publications and other scientific activities) and the 
bibliometric reports. All documents were delivered to the panellists for examination. 
Traditional bibliometrics can be reasonably done mainly in medicine, biosciences and natural sciences 
when using the Web of Science database, for example. Bibliometrics, provided by CWTS/The Centre for 
Science and Technology Studies, University of Leiden, cover only the publications that include WoS 
identification in the TUHAT-RIS. 
Traditional bibliometrics are seldom relevant in humanities and social sciences because the 
international comparable databases do not store every type of high quality research publications, such as 
books and monographs and scientific journals in other languages than English. The Helsinki University 
Library has done analysis to the RCs, if their publications were not well represented in the Web of Science 
databases (RCs should have at least 50 publications and internal coverage of publications more than 40%) 
– it meant 58 RCs. The bibliometric material for the evaluation panels was available in June 2011. The RC-
specific bibliometric reports are attached at the end of each report. 
The panels were provided with the evaluation material and all other necessary background information, 
such as the basic information about the University of Helsinki and the Finnish higher education system. 
 
Evaluation material 
1. Registration documents of the RCs for the background information 
2. Self evaluation material – answers to the evaluation questions 
3. Publications and other scientific activities based on the TUHAT RIS: 
3.1. statistics of publications 
3.2. list of publications 
3.3. statistics of other scientific activities 
3.4. list of other scientific activities 
4. Bibliometrics and comparable analyses: 
4.1. Analyses of publications based on the verification of TUHAT-RIS publications with the Web 
of Science publications (CWTS/University of Leiden) 
4.2. Publication statistics analysed by the Helsinki University Library - mainly for humanities and 
social sciences 
5. University level survey on doctoral training (August 2011) 
6. University level analysis on publications 2005–2010 (August 2011) provided by CWTS/University 
of Leiden 
 
Background material 
 
University of Helsinki 
- Basic information about the University of the Helsinki 
- The structure of doctoral training at the University of Helsinki 
- Previous evaluations of research at the University of Helsinki – links to the reports: 1998 and 2005 
 
The Finnish Universities/Research Institutes 
- Finnish University system 
- Evaluation of the Finnish National Innovation System 
- The State and Quality of Scientific Research in Finland. Publication of the Academy of Finland 
9/09. 
 
The evaluation panels were provided also with other relevant material on request before the meetings in 
Helsinki. 
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1.6 Evaluation questions and material 
The participating RCs answered the following evaluation questions which are presented according to the 
evaluation form. In addition, TUHAT RIS was used to provide the additional material as explained. For 
giving the feedback to the RCs, the panellists received the evaluation feedback form constructed in line 
with the evaluation questions: 
 
1. Focus and quality of the RC’s research 
 Description of 
- the RC’s research focus. 
- the quality of the RC’s research (incl. key research questions and results) 
- the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
The additional material: TUHAT compilation of the RC’s publications, analysis of the RC’s publications data 
(provided by University of Leiden and the Helsinki University Library) 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
2. Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
- recruitment and selection of doctoral candidates 
- supervision of doctoral candidates 
- collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
- good practises and quality assurance in doctoral training 
- assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
The additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
3. The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with 
public, private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral 
training. 
The additional material: TUHAT compilation of the RC’s other scientific activities. 
A written feedback from the aspects of: societal impact, national and international collaboration, 
innovativeness 
 
  Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
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4. International and national (incl. intersectoral) research collaboration and researcher mobility 
 Description of  
- the RC’s research collaborations and joint doctoral training activities 
- how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and 
researcher mobility, and the actions planned for their development. 
A written feedback from the aspects of: scientific quality, national and international collaboration 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
5. Operational conditions  
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the 
actions planned for their development. 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
6. Leadership and management in the researcher community 
 Description of 
- the execution and processes of leadership in the RC 
- how the management-related responsibilities and roles are distributed in the RC 
- how the leadership- and management-related processes support 
- high quality research 
- collaboration between principal investigators and other researchers in the RC 
the RC’s research focus 
- strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and 
the actions planned for developing the processes 
 
7. External competitive funding of the RC 
 The RCs were asked to provide information of such external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
- the administrator of the funding is/has been the University of Helsinki 
 On the e-form the RCs were asked to provide: 
1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, TEKES/The 
Finnish Funding Agency for Technology and Innovation , EU, ERC, foundations, other national funding 
organisations, other international funding organisations), and 
2)The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005–31.12.2010. 
 
Competitive funding reported in the text is also to be considered when evaluating this point. 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness, future significance 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
8. The RC’s strategic action plan for 2011–2013 
 RC’s description of their future perspectives in relation to research and doctoral training. 
A written feedback from the aspects of: scientific quality, scientific significance, societal Impact, processes 
and good practices related to leadership and management, national and international collaboration, 
innovativeness, future significance 
 Strengths 
 Areas of development 
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 Other remarks 
 Recommendations 
 
9. Evaluation of the category of the RC in the context of entity of the evaluation material (1-8) 
 
The RC’s fitness to the chosen participation category 
A written feedback evaluating the RC’s fitness to the chosen participation category  
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
10. Short description of how the RC members contributed the compilation of the stage 2 material 
Comments on the compilation of evaluation material 
 
11. How the UH’s focus areas are presented in the RC’s research? 
Comments if applicable 
 
12. RC-specific main recommendations based on the previous questions 1–11 
 
13. RC-specific conclusions 
1.7 Evaluation criteria 
The panellists were expected to give evaluative and analytical feedback to each evaluation question 
according to their aspects in order to describe and justify the quality of the submitted material. In 
addition, the evaluation feedback was asked to be pointed out the level of the performance according to 
the following classifications: 
 outstanding  (5) 
 excellent  (4) 
 very good  (3) 
 good   (2) 
 sufficient  (1) 
 
Evaluation according to the criteria was to be made with thorough consideration of the entire 
evaluation material of the RC in question. Finally, in questions 1-4 and 9, the panellists were expected to 
classify their written feedback into one of the provided levels (the levels included respective descriptions, 
‘criteria’). Some panels used decimals in marks. The descriptive level was interpreted according to the 
integers and not rounding up the decimals by the editors. 
 
Description of criteria levels 
Question 1 – FOCUS AND QUALITY OF THE RC’S RESEARCH 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Outstandingly strong research, also from international perspective. Attracts great international 
interest with a wide impact, including publications in leading journals and/or monographs published 
by leading international publishing houses. The research has world leading qualities. The research 
focus, key research questions scientific significance, societal impact and innovativeness are of 
outstanding quality. 
In cases where the research is of a national character and, in the judgement of the evaluators, should 
remain so, the concepts of ”international attention” or ”international impact” etc. in the grading 
criteria above may be replaced by ”international comparability”. 
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Operations and procedures are of outstanding quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are in 
alignment with the documentation. The ambition to develop the community together is of 
outstanding quality. 
Excellent quality of procedures and results (4) 
Research of excellent quality. Typically published with great impact, also internationally. Without 
doubt, the research has a leading position in its field in Finland. 
Operations and procedures are of excellent quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of excellent quality. 
Very good quality of procedures and results (3) 
The research is of such very good quality that it attracts wide national and international attention. 
Operations and procedures are of very good quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of very good quality. 
Good quality of procedures and results (2) 
Good research attracting mainly national attention but possessing international potential, 
extraordinarily high relevance may motivate good research. 
Operations and procedures are of good quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to large extent in alignment with the documentation. The ambition to develop the 
community together is of good quality. 
Sufficient quality of procedures and results (1) 
In some cases the research is insufficient and reports do not gain wide circulation or do not have 
national or international attention. Research activities should be revised. 
Operations and procedures are of sufficient quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to some extent in alignment with the documentation. The ambition to develop the 
community together is of sufficient quality. 
 
Question 2 – DOCTORAL TRAINING 
Question 3 – SOCIETAL IMPACT 
Question 4 – COLLABORATION 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Procedures are of outstanding quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are in alignment with the 
documentation. The ambition to develop the community together is of outstanding quality. The 
procedures and results are regularly evaluated and the feedback has an effect on the planning. 
Excellent quality of procedures and results (4) 
Procedures are of excellent quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of excellent quality. The 
procedures and outcomes are evaluated and the feedback has an effect on the planning. 
Very good quality of procedures and results (3) 
Procedures are of very good quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
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management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of very good quality. 
Good quality of procedures and results (2) 
Procedures are of good quality, shared occasionally in the community. The practices and quality of 
doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of good quality. 
Sufficient quality of procedures and results (1) 
Procedures are of sufficient quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are occasionally documented and operations and practices are to some extent in 
alignment with the documentation. The ambition to develop the community together is of sufficient 
quality. 
 
Question 9 – CATEGORY 
Participation category – fitness for the category chosen 
The choice and justification for the chosen category below should be reflected in the RC’s responses to the 
evaluation questions 1–8. 
1. The research of the participating community represents the international cutting edge in its field. 
2. The research of the participating community is of high quality, but the community in its present 
composition has yet to achieve strong international recognition or a clear break-through. 
3. The research of the participating community is distinct from mainstream research, and the special 
features of the research tradition in the field must be considered in the evaluation. The research is 
of high quality and has great significance and impact in its field. However, the generally used 
research evaluation methods do not necessarily shed sufficient light on the merits of the 
research.  
4. The research of the participating community represents an innovative opening. A new opening can 
be an innovative combination of research fields, or it can be proven to have a special social, 
national or international demand or other significance. Even if the researcher community in its 
present composition has yet to obtain proof of international success, its members can produce 
convincing evidence of the high level of their previous research. 
5. The research of the participating community has a highly significant societal impact. The 
participating researcher community is able to justify the high social significance of its research. 
The research may relate to national legislation, media visibility or participation in social debate, 
or other activities promoting social development and human welfare. In addition to having 
societal impact, the research must be of a high standard. 
 
An example of outstanding fitness for category choice (5) 5 
The RC’s representation and argumentation for the chosen category were convincing. The RC recognized 
its real capacity and apparent outcomes in a wider context to the research communities. The specific 
character of the RC was well-recognized and well stated in the responses. The RC fitted optimally for the 
category. 
 
 Outstanding  (5) 
 Excellent  (4) 
 Very good  (3) 
 Good   (2) 
 Sufficient  (1) 
The above-mentioned definition of outstanding was only an example in order to assist the panellists in 
the positioning of the classification. There was no exact definition for the category fitness. 
                                                                
5 The panels discussed the category fitness and made the final conclusions of the interpretation of it. 
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1.8 Timetable of the evaluation 
The main timetable of the evaluation: 
1. Registration   November 2010 
2. Submission of self-evaluation materials  January–February 2011 
3. External peer review    May–September 2011 
4. Published reports    March–April 2012 
- University level public report 
- RC specific reports 
 
The entire evaluation was implemented during the university’s strategy period 2010–2012. The preliminary 
results were available for the planning of the following strategy period in late autumn 2011. The evaluation 
reports will be published in March/April 2012. More detailed time schedule is published in the University 
report. 
1.9 Evaluation feedback – consensus of the entire panel 
The panellists evaluated all the RC-specific material before the meetings in Helsinki and mailed the 
draft reports to the evaluation office. The latest interim versions were on-line available to all the panellists 
on the Wiki-sites. In September 2011, in Helsinki the panels discussed the material, revised the first draft 
reports and decided the final numeric evaluation. After the meetings in Helsinki, the panels continued 
working and finalised the reports before the end of November 2011. The final RC-specific reports are the 
consensus of the entire panel. 
The evaluation reports were written by the panels independently. During the editing process, the 
evaluation office requested some clarifications from the panels when necessary. The tone and style in the 
reports were not harmonized in the editing process. All the reports follow the original texts written by the 
panels as far as it was possible. 
The original evaluation material of the RCs, provided for the panellists is attached at the end of the 
report. It is essential to notice that the exported lists of publications and other scientific activities depend 
how the data was stored in the TUHAT-RIS by the RCs. 
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2 Evaluation feedback 
2.1 Focus and quality of the RC’s research 
 Description of 
 the RC’s research focus 
 the quality of the RC’s research (incl. key research questions and results) 
 the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness 
 
The RC is focusing on research in medicinal chemistry in different fields of cancer, antibiotics, metabolics 
and GPCR. As a relative small group they have been being quite productive concerning paper and patents. 
In these different fields they have achieved excellent/very good results that have been published in the 
leading journals in that field. The work has been successfully supported by many EU grants as well as 
different national sources. The international network has greatly been enhanced by these European and 
world-wide structures. 
With the relative small size of the groups the potential overlap in the topics can be used in a greater 
extend to have a greater synergistic effect and even higher output. The RC could define their “spearhead” 
projects for this collaboration. In this respect, the potential for co-operations within the UH also existing in 
many parts, can still be enlarged. Interaction with industry, apparently very limited at present, should be 
encouraged both for scientific debate in the field and for training and funding opportunities. 
Numeric evaluation: 3.5 (Very good)  
2.2 Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
 recruitment and selection of doctoral candidates 
 supervision of doctoral candidates 
 collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
 good practises and quality assurance in doctoral training 
 assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
 Additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
ASPECTS: Processes and good practices related to leadership and management 
 
There is an excellent/good and well organized training program for the PhD students. The outlook for 
good positions is good although the general number of free position for excellent academics is limited. 
The teaching work-load for the PhD students as well as for the supervisors at different levels is not clear, 
but the impression seems that there may be an overload or misbalance of too much teaching giving a 
smaller part for research. 
The overall duration of PhD studies seems generally too long as compared to international standards. 
This has been well identified in RC. The practice of the needed publications should be work-on to find a 
balanced adaption. The difficulty with a general judgment of number of publications, problems with 
impact factors etc. has largely been discussed in other work, but quality should always be better handled 
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than quantity. Based on the statistics tables provided, the quality indicators, such as MNCS, should still be 
improved. 
With the different faculties there seems to be different PhD student programs. With a general core 
structure on a number of RCs or faculties and then different specialized course for the detailed problems 
of the RC the work-load may be reduced and the outcome increased. A template or RC specific set of 
guidelines to outline a unified process and good practice and governance may be helpful for both 
doctorate candidates and supervisors. 
Numeric evaluation: 3 (Very good) 
2.3 The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral training. 
 Additional material: TUHAT compilation of the RC’s other scientific activities. 
ASPECTS: Societal impact, national and international collaboration, innovativeness 
 
The fields of cancer, GPCR as well of drug misuse have great impact on society and receive great interest. 
The efforts in achieving external recognition for the RC’s work in drugs of misuse and illicit drugs should 
be elevated domestically and internationally and such investment of time may lead to additional sources 
of funding from various agencies (e.g. international sports agencies, forensic agencies). Since some 
antibiotics become ineffective against some bacteria etc. there is also an increasing need for new 
antibiotics which are rarely covered by pharmaceutical industry. 
New findings in the main research topics may drastically change the therapy of different diseases and 
the health situation. 
The RC has improved concerning the international exchange during the last evaluation period and this 
trend should be further worked out. 
The output to non-scientific community and the communication may be increased to help on the 
general acceptance and understanding on the time-scale and money consumption with drug development. 
Indicators of research excellence, such as post of academy professor, status for a center of excellence 
or successful ERC grants, should actively be strived for. Those would significantly improve the recognition 
of RC. 
Numeric evaluation: 3 (Very good) 
2.4 International and national (incl. intersectoral) research 
collaboration and researcher mobility 
 Description of  
 the RC’s research collaborations and joint doctoral training activities 
 how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and researcher 
mobility, and the actions planned for their development. 
ASPECTS: Scientific quality, national and international collaboration 
 
The RC has improved the international exchange during the last evaluation period and this trend should be 
further worked out. 
Numerous exchange programs are performed with other European countries. The full potential of short 
termed exchange missions within COST or other programs has not been taken full advantage. The 
potential for UH co-operations can also to be increased as some connections are striking with the 
inspection of different RCs. 
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PhD student exchange from and to UH may be increased to get a higher level of international exchange 
in information and needed instrumentation. 
Numeric evaluation: 3 (Very good) 
2.5 Operational conditions 
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the actions 
planned for their development. 
ASPECTS: Processes and good practices related to leadership and management 
 
Administrative work and teaching duties seem to take a lot of time from research. It may have some 
advantage to have an effective administration asking the researchers what they can do for them and in 
which way administration may help the researchers. Quite often the administration has developed and 
increased themselves with higher bureaucracy etc. With the development of new administrative structures 
the ways may have get longer instead of shorter and more direct/problem oriented. This does not seem to 
be specific for this RC, it seems to be a more or less general problem with all universities. 
The RC is linked to two administrative units – Division of Pharmaceutical Chemistry and the Centre for 
Drug Research. It is not clear, what are the relationships between the RC and these units in terms of 
governance and management. 
2.6 Leadership and management in the researcher community 
 Description of  
 the execution and processes of leadership in the RC 
 how the management-related responsibilities and roles are distributed in the RC 
 how the leadership- and management-related processes support 
 high quality research 
 collaboration between principal investigators and other researchers in the RC 
 the RC’s research focus 
 strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and the 
actions planned for developing the processes 
ASPECTS: Processes and good practices related to leadership and management 
 
Despite a clear hierarchy the RC is led by a team consisted of the group leaders. They show together 
concerted actions and friendly agreement with decisions. Within the university, Division of Pharmaceutical 
Chemistry/DPC and Centre for Drug Research/CDR is not an easy task to discriminate different groups or 
research topics. 
Nevertheless, some more general guidelines for cooperative decision-making within the teams (fixed 
meeting dates, RC´s research area sharpening, equipment etc.) in organizational aspects as well as in case 
of conflicts may be useful. In this respect some more time of RC members in the general management 
would be useful which may be dampened by the workload with teaching and bureaucracy. 
The leadership role can be improved by UH or Finnish workshops on RC immanent topics as well as 
with an application within a larger consortium having one of the leading positions within the next few 
years. 
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2.7 External competitive funding of the RC 
• The RCs were asked to provide information of such external competitive funding, where: 
• the funding decisions have been made during 1.1.2005–31.12.2010, and  
• the administrator of the funding is/has been the University of Helsinki 
• On the e-form the RCs were asked to provide: 
1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, 
TEKES/The Finnish Funding Agency for Technology and Innovation, EU, ERC, foundations, other 
national funding organisations, other international funding organizations), and 
2) The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005–31.12.2010. 
Competitive funding reported in the text is also to be considered when evaluating this point. 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness and future significance 
 
The RC made an excellent external funding with huge amounts of money for this community size (in total 
about 4 M€) which is above the usual budget for this kind of research. It shows the string competitive 
character of the group within the international scientific community. The diverse structure from national 
and international sources put this on a broad position. 
2.8 The RC’s strategic action plan for 2011–2013 
• RC’s description of their future perspectives in relation to research and doctoral training. 
ASPECTS: Scientific quality, scientific significance, societal Impact, processes and good practices related to 
leadership and management, national and international collaboration, innovativeness, future significance 
 
The interdisciplinary approach on many topics is highly appreciated. 
The focus on the overlap of existing projects seems to highly useful for the next period. Some tight 
scientific connections to other RCs may be underestimated so far and need further inspection (e.g. HYRL, 
BNMTI, MAC etc.). 
The cooperation with the other related organizations and RCs should be defined. 
2.9 Evaluation of the category of the RC in the context of entity of 
the evaluation material (1-8) 
The RC’s fitness to the chosen participation category. 
Category 4. The research of the participating community represents an innovative opening. 
 
The RC is one of the national leading research teams in Medicinal Chemistry. It has achieved good 
internationalization and output in form of paper and patents. The innovative character has highly 
increased within the last evaluation period. 
Within the relative small RC size they have achieved high output and very good visibility. The positive 
trend for research excellence is advancing. 
The chosen category is well taken although other possibilities may also be considered with the further 
focus in research. 
Numeric evaluation: 4 (Excellent) 
 
 
 
 
19 
 
2.10 Short description of how the RC members contributed the 
compilation of the stage 2 material 
The processes employed were fair and appropriate. 
2.11 How the UH’s focus areas are presented in the RC’s research 
Focus area 1: the basic structure, materials and natural resources of the physical world 
 
It was obvious from the presentation that MEDCHEMBIO belongs to several focus areas due its 
multidisciplinarity in life sciences. The relevant focus areas are covered by the chosen scientific fields of 
the RC. 
2.12 RC-specific main recommendations 
The clear advantage for more focused and condensed research areas within this rather small RC can be 
seen. 
The exchange of PhD students could be increased and thereby helping to increase the international 
visibility of this excellent RC. 
2.13 RC-specific conclusions 
The RC already has a high level of local, domestic and international co-operations and network. Additional 
approaches for further industrial contacts may help to take translational steps in research. 
2.14 Preliminary findings in the Panel-specific feedback 
The RC has performed excellent to good research in different fields of medicinal chemistry with a slightly 
too high number of different topics/targets. 
The doctoral training is well-organized and introduced in different doctoral programs. Any overlap in 
teaching may here be reduced by the reorganization of strongly related teaching stuff. The outcome for 
society is excellent with these highly educated valuable scientists with a very good to excellent 
international network. 
Nationally they have achieved a good leadership position, but the clear role to the different research 
units have still to be defined and some breakthrough findings are to be awaited. 
With the small size of the group they have achieved a broad and diverse funding at a very high level. 
With the plans for the future an additional sharpening of the foci would help to drive the high potential 
of the RC into new findings and may be into further translational steps for drug development. 
2.15 Preliminary findings in the University-level evaluation 
The RC has focused in different fields of medicinal chemistry. Some overlap in some topics of other RCs 
has been identified which may broaden the possibilities to study some to the focused topics into more 
details and at an even higher scientific level. These co-operations may then be used to take additional 
steps for drug development or metabolism studies for translational research. 
The studies in these fields of life sciences have great societal impact. 
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The national and international network is already at a high level. Further stress into the broadening of 
this may have advantages for the exchange of PhD students and the international visibility. 
The external funding is at an excellent level for this size of RC. This is especially true since funding for 
such basic and essential topics are usually difficult to find. 
The strategic plan is a continuation of the previously successful research. The advantage of thematic 
overlap within the RC and within other local RC could strengthen the performance of the group as well as 
that of its (new) partners. 
The group has published in the leading journals in this field and has taken some patents for further 
development. The networking within the scientific community of UH and of Finland in this life sciences 
needs further enhancement as the need and the demand for success is very high in this area. 
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3 Appendices 
A. Original evaluation material 
a. Registration material – Stage 1 
b. Answers to evaluation questions – Stage 2 
c. List of publications 
d. List of other scientific activities 
B. Bibliometric analyses 
a. Analysis provided by CWTS/University of Leiden 
b. Analysis provided by Helsinki University Library (66 RCs) 
 
 
 
 
 
International evaluation of research and doctoral training 
at the University of Helsinki 2005-2010 
 
         RC-SPECIFIC MATERIAL FOR THE PEER REVIEW 
 
 
 
 
NAME OF THE RESEARCHER COMMUNITY:  
Medicinal Chemistry and Biochemistry Research Group (MEDCHEMBIO) 
 
LEADER OF THE RESEARCHER COMMUNITY:  
Professor Jari Yli-Kauhaluoma, Faculty of Pharmacy 
 
 
RC-SPECIFIC MATERIAL FOR THE PEER REVIEW: 
 Material submitted by the RC at stages 1 and 2 of the evaluation 
- STAGE 1 material: RC’s registration form (incl. list of RC participants in an excel table) 
- STAGE 2 material: RC’s answers to evaluation questions 
 TUHAT compilations of the RC members’ publications 1.1.2005-31.12.2010 
 TUHAT compilations of the RC members’ other scientific activities 1.1.2005-31.12.2010 
 Web of Science(WoS)-based bibliometrics of the RC’s publications data 1.1.2005-31.12.2010 
(analysis carried out by CWTS, Leiden University) 
NB! Since Web of Science(WoS)-based bibliometrics does not provide representative results for most RCs representing 
humanities, social sciences and computer sciences, the publications of these RCs will be analyzed by the UH Library 
(results available by the end of June, 2011) 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
 
 
Name: Yli-Kauhaluoma, Jari 
E-mail:  
Phone: 09-19159170 
Affiliation: Professor, Head of Division, Vice-director of the GS in Pharmaceutical Research 
Street address: Faculty of Pharmacy, Division of Pharmaceutical Chemistry,Viikinkaari 5 E (PO Box 56), 
00014 University of Helsinki 
 
 
Name of the participating RC (max. 30 characters): Medicinal Chemistry and Biochemistry Research Group 
Acronym for the participating RC (max. 10 characters): MEDCHEMBIO 
Description of the operational basis in 2005-2010 (eg. research collaboration, joint doctoral training 
activities) on which the RC was formed (MAX. 2200 characters with spaces): The Medicinal Chemistry and 
Biochemistry Research Group (MEDCHEMBIO), combines the medicinal chemistry-related research efforts 
of four principal investigators of the Faculty of Pharmacy in a coherent and complementary manner. The 
focus is medicinal chemistry, which is a chemistry-based discipline, also involving aspects of biological, 
medical and pharmaceutical sciences. Medicinal chemistry is concerned with the invention, discovery, 
design, identification and preparation of biologically active compounds, the study of their metabolism, the 
interpretation of their mode of action at the molecular level and the construction of structure-activity 
relationships.  
 
The principal investigators and their key expertise are Dr. Moshe Finel (research group leader, docent of 
medical chemistry, research focus biochemistry of drug metabolism), Dr. Erik Wallén (research group 
leader, docent of medicinal chemistry, research focus synthesis of peptidomimetics), Dr. Henri Xhaard 
(research group leader, research focus computer-aided drug design and cheminformatics) and Dr. Jari Yli-
Kauhaluoma (professor of medicinal chemistry, research group leader, research focus medicinal, organic 
and natural product chemistry). 
 
All the principal investigators of the MEDCHEMBIO researcher community have collaborated with each 
other during the evaluation period and, between them, have been in charge of joint doctoral training and 
supervision of 22 PhD students, as well as involved in the supervision of 9 PhD students not belonging to 
this RC. The combined research activity of the RC members yielded 112 scientific articles and 5 PhD degrees 
during 2005-2010. 
 
 
1 RESPONSIBLE PERSON 
2 DESCRIPTION OF THE PARTICIPATING RESEARCHER COMMUNITY (RC) 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
 
 
Main scientific field of the RC’s research: natural sciences 
RC's scientific subfield 1: Chemistry, Medicinal 
RC's scientific subfield 2: Pharmacology and Pharmacy 
RC's scientific subfield 3: Chemistry, Organic 
RC's scientific subfield 4: Biochemistry and Molecular Biology 
Other, if not in the list:  
 
 
Participation category: 4. Research of the participating community represents an innovative opening 
Justification for the selected participation category (MAX. 2200 characters with spaces):  The 
MEDCHEMBIO researcher community combines various disciplines, such as pharmaceutical sciences, 
organic chemistry, biochemistry, molecular biology, theoretical and computational chemistry as well as 
biology in its research. 
 
The MEDCHEMBIO group started its research projects with a focus on the discovery of new bioactive 
compounds and study of their metabolism, particularly glucuronidation, in 2004 with two principal 
investigators (the number of principal investigators increased to three in 2007 and to four in 2008). 
Noteworthy, the first professorship in medicinal chemistry at the University of Helsinki was established in 
the Faculty of Pharmacy in 2006, and it is the only professorship in synthetic medicinal chemistry in the 
whole country. 
 
The various research projects of the MEDCHEMBIO group have resulted in 112 publications in high-quality 
journals (e.g. J. Med. Chem., DMD, Mol. Pharmacol., Org. Lett.) and 6 patent applications during the 
evaluation period, an indication of the innovation of the MEDCHEMBIO group. 
 
The laboratories that participate in this group have developed new methodologies that were not available 
at the University of Helsinki before, such as combinatorial chemistry, peptidomimetics, full set of 19 human 
UDP-glucuronosyltransferase enzymes for glucuronidation studies, GPCR modeling, studies of 
semisynthetic natural compounds as antimicrobial and antiviral agents, as well as design and synthesis of 
compounds targeted at protein kinases. An additional strength of the MEDCHEMBIO is that the key 
activities in computer-aided methods, synthesis and biochemistry are present in the same researcher 
community. These lines of research are all integral part of modern drug discovery and add important new 
possibilities for both researchers and doctoral training. 
 
 
Public description of the RC's research and doctoral training (MAX. 2200 characters with spaces): The 
Medicinal Chemistry and Biochemistry Research Group (MEDCHEMBIO) has been focusing on drug 
3 SCIENTIFIC FIELDS OF THE RC 
4 RC'S PARTICIPATION CATEGORY 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
discovery and on applying and developing methods in medicinal chemistry, particularly synthetic organic 
chemistry, molecular modelling and drug metabolism. The MEDCHEMBIO group is the only group at the 
University that is translating the increasing structural information of drug targets or ligands (biologically 
active natural compounds or peptides) into the synthesis of small molecular weight compounds that are 
original and unavailable from current commercial compound libraries. 
The research of the group is focused on chemotherapeutics, mainly against cancer (kallikreins and protein 
kinases, such as PKC, ALK, Pim) but also against intracellular pathogenic bacteria (Chlamydia), alphaviruses 
and parasites (Leishmania). The compounds serve, or will serve, as probes in the research of new drug 
targets and as hits or leads in the search for new therapeutic compounds. Moreover, the methodologies 
used by the group have a wide general applicability and could be applied to other types of projects, beyond 
medicinal chemistry, such as chemical biology and more. For example, the biologically active compounds 
can be used as specific probes for studying the biochemical function or cellular localization of enzymes and 
other proteins. 
The metabolism studies of the MEDCHEMBIO group incorporate steroid metabolism and UDP-
glucuronosyltransferases (UGTs) research, which is mainly centered on the glucuronidation of drugs and 
endogenous compounds. The group has an internationally unique source of all the 19 human UGTs as 
recombinant proteins. The UGTs research and gained expertise are also at the basis of several productive 
scientific collaborations and the success of this research direction efficiently links various research teams 
beyond MEDCHEMBIO. 
The research in the MEDCHEMBIO group has resulted in 5 PhD degrees during the evaluation period. 
Doctoral training is closely linked to the Graduate School in Pharmaceutical Research and National GS in 
Informational and Structural Biology. We are also actively collaborating with the GS in Organic Chemistry 
and Chemical Biology. 
Significance of the RC's research and doctoral training for the University of Helsinki (MAX. 2200 
characters with spaces): The Medicinal Chemistry and Biochemistry Research Group contributes to the 
joint research efforts and doctoral training of the University of Helsinki in several ways. It provides a unique 
combination of scientific expertise in medicinal chemistry with three different main lines: synthetic 
medicinal chemistry, computational medicinal chemistry and drug metabolism, bridging academic and 
industrial drug discovery and development. 
 
The MEDCHEMBIO group has established a close collaboration with many domestic and international 
research groups that are active in biological screening and research of new drug targets. It also coordinates 
and participates in various European Community-funded projects and research networks, such as Protein 
Kinase Research, LIINTOP, FORESTSPECS, MAREX and the COST Programme “New drugs for neglected 
diseases” among others. We have gained valuable experience in these highly collaborative, 
multidisciplinary and international projects both as coordinators and as active contributors. 
 
Finally, the MEDCHEMBIO group focuses on several aspects of drug discovery and the group is applying and 
developing methods in modern medicinal chemistry, most importantly synthetic organic chemistry, 
molecular modelling, and drug metabolism. The MEDCHEMBIO is the only group at the University of 
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Helsinki that combines synthetic, computational and biochemical methods in medicinal chemistry and 
translates the increasing structural information of drug targets or ligands into new, small molecular weight 
compounds. 
Keywords: medicinal chemistry, drug discovery, drug metabolism, molecular modelling, organic synthesis, 
pharmacy 
 
 
Justified estimate of the quality of the RC's research and doctoral training at national and international 
level during 2005-2010 (MAX. 2200 characters with spaces): A part of the current MEDCHEMBIO group 
(Wallén and Yli-Kauhaluoma) conducted a benchmarking self-assessment of the quality of their research 
and doctoral training at national and international levels for the Evaluation of Chemistry Research in 
Finland by the Academy of Finland in 2010. For that evaluation we had to suggest a reference unit and, 
rather than selecting a “regular” chemistry department, we suggested the Division of Medicinal Chemistry 
(DMC) at the Vrije Universiteit from the internationally highly-ranked Leiden/Amsterdam Center for Drug 
Research, as a reference for that self-evaluation exercise. Both our and the DMC units conduct medicinal 
chemistry research in similar environment of biological and pharmaceutical sciences and, therefore, the 
DMC is a very good group to compare to. 
 
The DMC in Amsterdam mainly approaches medicinal chemistry from the pharmacological perspective, 
while our group has strong organic chemistry and biochemical points of view. The number of our personnel 
is less than half of DMC’s, with the notable exception of the number of PIs, that being in Helsinki one-third 
of the Amsterdam’s DMC. Nevertheless, despite having less resources and being a significantly younger 
research group, our team has succeeded in publishing its key findings in similar level of scientific journals as 
the DMC unit. We have published some of its chemistry research even in higher-ranking journals than the 
DMC unit. For example, we had three articles in Organic Letters during the evaluation period, actually 
representing 21% of all the Finnish articles in this highest impact journal in the field of organic chemistry. 
 
N.B. The Academy of Finland evaluation was focused on the administratively defined chemistry units rather 
than the current evaluation of the Researcher Communities and this is why the research groups of PIs Finel 
and Xhaard were not part of that. The latter groups are members of the current RC for the University of 
Helsinki evaluation and the many additional publications of theirs were not included in the chemistry 
evaluation, but will be included in the current evaluation. 
Comments on how the RC's scientific productivity and doctoral training should be evaluated (MAX. 2200 
characters with spaces): We intend to use Leiden/Amsterdam Center for Drug Research for scientific 
“benchmarking” and self-evaluation purposes in the future, particularly if it maintains or improves its 
internationally high scientific level. The self-evaluation forms may serve as the basis for assessing the 
MEDCHEMBIO’s scientific productivity and doctoral training, once the contributions of the laboratories of 
Moshe Finel and Henri Xhaard that did not participate in the chemistry evaluation, have been added. The 
selection of the Dutch unit is supported by a thorough bibliometric analysis, including factors such as (i) the 
number of publications by the principal investigators during the evaluation period according to ISI Web of 
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Knowledge, (ii) the number of citations to these publications, (iii) average citations per item, and (iv) the 
group’s h-index. Other important factors are the quantity (number) and quality (grades, prizes) of the PhD 
theses finalized during the evaluation period, as well as the present employment of the graduated PhDs 
from the MEDCHEMBIO group. Assessing the innovativeness of the MEDCHEMBIO group, another 
important topic, should take into account submitted patent applications and granted patents. Finally, the 
quality of education, supervision and leadership practices of the MEDCHEMBIO doctoral training should be 
taken into account.  
 
The research results of the MEDCHEMBIO group projects have been and will be published in peer-reviewed 
international scientific journals and in international scientific conference proceedings (posters and oral 
presentations). The aim is to submit the manuscripts to the most appropriate journals in the field. Most 
influential journals of medicinal chemistry and drug metabolism are Journal of Medicinal Chemistry (impact 
factor 4.802) and Journal of Chemical Information and Modeling (IF 3.882) by the American Chemical 
Society’s as well as Drug Metabolism and Disposition (IF 3.743), Molecular Pharmacology (IF 4.531) and 
Journal of Pharmacology and Experimental Therapeutics (IF 4.093) by the American Society for 
Pharmacology and Experimental Therapeutics. If appropriate, Finnish and/or international patent 
applications will be filed. 
LIST OF RC MEMBERS
NAME OF THE RESEARCHER COMMUNITY: Medicinal Chemistry and Biochemistry Research Group (MEDCHEMBIO)
RC-LEADER J. Yli-Kauhaluoma
Category 4
Last name First name
PI-status 
(TUHAT, 
29.11.2010)
Title of research and 
teaching personnel Affiliation 
1 Finel Moshe x university researcher Faculty of Pharmacy
2 Wallén Erik x university lecturer Faculty of Pharmacy
3 Xhaard Henri x university researcher Faculty of Pharmacy
4 Yli-Kauhaluoma Jari x university researcher Faculty of Pharmacy
5 Aumüller Ingo postdoctoral researcher Faculty of Pharmacy
6 Harju Kirsi doctoral candidate - postdoctoral researcher Faculty of Pharmacy
7 Kiuru Paula postdoctoral researcher Faculty of Pharmacy
8 Laakkonen Liisa senior researcher Faculty of Pharmacy
9 Rajaratnam Mohanathas postdoctoral researcher Faculty of Pharmacy
10 Regad Leslie postdoctoral researcher Faculty of Pharmacy
11 Samanta Swapan postdoctoral researcher Faculty of Pharmacy
12 Tadd Andrew postdoctoral researcher Faculty of Pharmacy
13 Alakurtti Sami doctoral candidate Faculty of Pharmacy
14 Alkio Martti doctoral candidate Faculty of Pharmacy
15 Bichlmaier Ingo doctoral candidate Faculty of Pharmacy
16 Boije af Gennäs Gustav doctoral candidate Faculty of Pharmacy
17 Haavikko Raisa doctoral candidate Faculty of Pharmacy
18 Kaivosaari Sanna doctoral candidate Faculty of Pharmacy
19 Keurulainen Leena doctoral candidate Faculty of Pharmacy
20 Kiriazis Alexandros doctoral candidate Faculty of Pharmacy
21 Kurkela Mika doctoral candidate Faculty of Pharmacy
22 Leikoski Tuomo doctoral candidate Faculty of Pharmacy
23 Manevski Nenad doctoral candidate Faculty of Pharmacy
24 Meinander Kristian doctoral candidate Faculty of Pharmacy
25 Siiskonen Antti doctoral candidate Faculty of Pharmacy
26 Sipilä Julius doctoral candidate Faculty of Pharmacy
27 Sneitz Nina doctoral candidate Faculty of Pharmacy
28 Sten Taina doctoral candidate Faculty of Pharmacy
29 Stepniewski Michal doctoral candidate Faculty of Pharmacy
30 Vahermo Mikko doctoral candidate Faculty of Pharmacy
31 Wissel Gloria doctoral candidate Faculty of Pharmacy
32 Zhang Hongbo doctoral candidate Faculty of Pharmacy
33 Zhang Yuezhou doctoral candidate Faculty of Pharmacy
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Name of the RC’s responsible person: Yli-Kauhaluoma, Jari 
E-mail of the RC’s responsible person:   
Name and acronym of the participating RC: Medicinal Chemistry and Biochemistry Research Group, 
MedChemBio 
The RC’s research represents the following key focus area of UH: 1. Maailman perusrakenne, materiaalit ja 
luonnonvarat – The basic structure, materials and natural resources of the physical world 
Comments for selecting/not selecting the key focus area: The key words of the MedChemBio researcher 
community directly related to the selection of the selected key focus areas are medicinal chemistry, drug 
metabolism, drug discovery, computational modelling, chemoinformatics, chemistry, biology, medicines. 
This is why we have chosen both “The basic structure, materials and natural resources of physical world” 
and “Welfare and safety” as our key focus areas from the University list. 
 
 
 Description of the RC’s research focus, the quality of the RC’s research (incl. key research 
questions and results) and the scientific significance of the RC’s research for the research 
field(s).  
The main foci of RC are 1. Design, synthesis & biological evaluation of new compounds and 
modifications of known compounds leading to improved understanding of their structure-activity 
relationships (SAR); 2. Molecular biological studies to improve understanding of compounds recognition 
and drug metabolism; 3. Computational studies to provide fresh insight into SAR of compound series 
that are of current general interest or other available data that advance medicinal chemistry knowledge; 
4. Studying the influence of compounds and proteins structure on biotransformation and 
pharmacokinetics; 5. Education of highly qualified researchers for both academia and industry. 
Description of the RC research: 
1. Cancer chemotherapy is one of the RC’s main themes and our research has been focused on protein 
kinases and kallikreins. In EC and Academy of Finland (AF)-funded projects we have developed inhibitors 
for protein kinase C (PKC) isoenzymes, particularly new regulatory domain-targeted compounds. This led 
to the discovery of isophthalates as a new class of ligands affecting PKC activation with antiproliferative 
effects. Our PKC catalytic domain compounds combine inhibitory activity and cell penetration ability in a 
single molecule. We have supplied the ProKinase Consortium Library with >400 kinase-targeted in-house 
compounds and synthesized analogs of bistramide A (PKC-modulating natural compound) together with 
P. Goekjian. The collaboration with L. Scapozza and C. Gambacorti resulted in a series of new and 
selective urea-based inhibitors targeted at the catalytic site of anaplastic lymphoma kinase. In 
collaboration with P. Koskinen we have discovered heptafulvenes and tropones as a new class of potent 
Pim family kinase inhibitors that efficiently block many Pim-dependent cellular functions. These cell-
permeable pan-Pim inhibitors can be used not only as efficient research tools, but also as promising hits 
against tumors overexpressing Pim kinases. 
The human kallikreins (KLK) are a family of 15 closely related serine proteases. In addition to other roles, 
KLK3 has an antiangiogenic effect. There are few peptides that have the unique biological activity of 
stimulating KLK3 and we are interested in developing peptidomimetics of these peptides. An AF-funded 
project was started by studying the most active bicyclic peptide made up of 13 amino acids with two 
disulfide bridges. The non-terminal disulfide bridge was first investigated by replacing it with different 
BACKGROUND INFORMATION 
1 FOCUS AND QUALITY OF RC'S RESEARCH (MAX. 8800 CHARACTERS WITH SPACES) 
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hydrocarbon cross linkers. As a first result, the synthetic routes to the cross linkers have been published. 
The final aim is to transfer the peptide into a non-peptidic scaffold. The most important collaborator is 
K. Luthman. The computational part of the project is performed in collaboration with A. Poso. The RC is 
also using structural bioinformatics for peptide modeling and to identify privileged chemical structures 
among inhibitors of serine proteases. 
2. New bioactive compounds against intracellular pathogens. With financial support from EC, Tekes and 
many foundations we have explored betulin, a main terpene constituent of the birch bark waste of a 
forest industry, as a starting material for pharmaceutical applications. The main results, in collaboration 
with C. Jaffe, K. Janda, P. Vuorela and P. Tammela, have been the discovery of semisynthetic betulin 
derivatives as antimicrobial agents against various intracellular pathogens and viruses, such as. L. 
donovani, C. botulinum, C. pneumoniae and alphaviruses. We have also designed and synthesized 2-aryl 
benzimidazoles that inhibit the growth of Chlamydiae. Another line of forest waste research, funded by 
Forestcluster, has resulted in abietane derivatives inhibiting growth of Leishmania parasites and 
preventing formation of Staphylococcus biofilms. Computational methods have been used to study SAR 
of these compounds and to construct a related chemogenomic map of diseases and targets. 
3. Metabolism of drugs, other xenobiotics and lipophilic endogenous compounds. We have been 
cloning, expressing and studying the human UDP-glucuronosyltransferase enzymes (UGTs) to gain better 
understanding of human drug metabolism and related processes. These enzymes catalyze the 
conjugation of many drugs and other small lipophilic molecules with glucuronic acid, thereby often 
inactivating them and stimulating their excretion from the body. We have a unique collection of 19 
human UGTs as recombinant proteins and use them for multiple studies, such as on substrate specificity 
of individual UGTs. In these studies we also employ compounds synthesized in the RC, such as the high 
selectivity inhibitors of individual UGTs. Among our main research topics have also been the 
glucuronidation of steroids and extrahepatic drug glucuronidation. Computational models of UGTs 
structure, active sites and substrate binding are currently being developed. Our UGTs research, enzymes 
and mutants have been the basis of productive scientific collaborations with different laboratories, both 
domestic and international. The major funding has been from UH, AF, EC, Juselius Foundation and GSPR. 
4. G protein-coupled receptors (GPCRs) are an important class of drug targets and 40% of drugs 
currently on the market are targeted at them. Funding from UH was obtained, in collaboration with J. 
Kukkonen, for developing compounds active toward the orexin receptors. The RC has developed 
compounds active at the alpha-2 adrenergic receptors in collaboration with M. Scheinin. Efforts have 
also been made to develop new computational tools and assess existing tools, supported by ISB 
Graduate School. 
During 2005-10 our RC has published 112 scientific articles in international peer-reviewed journals. Our 
research has yielded 1 patent and 8 patent applications, and we have supervised 5 completed PhD 
degrees. We have been in charge of supervision of a total of 22 PhD students (incl. the completed 
studies) and involved in supervision of 9 PhD students not belonging to this RC. We have published our 
research in journals such as J. Med. Chem., Org. Lett., Mol. Pharmacol. & Drug Metab. Dispos., all among 
the top journals in the field. The RC members have given many presentations in international meetings. 
We have been particularly successful in obtaining highly-competed EC and AF funding for our research, 
the respective shares of the total RC external funding being 33% and 23%. 
For self evaluation of our research, we have been using the Division of Medicinal Chemistry (DMC) from 
the internationally high-ranked Leiden/Amsterdam Center for Drug Research as a reference point. Both 
we and them conduct medicinal chemistry research in a similar environment of biological and 
pharmaceutical sciences and not, for example, in chemistry departments of the respective universities. 
The following is bibliometric data of DMC and our RC during 2005-10, respectively: number of articles 
114, 112; citations to articles 1741, 811; h-index based on the articles 21, 16; and average citation per 
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item 15.27, 7.24. According to these parameters, the quality of our RC research starts to approach that 
of the DMC. This is despite having significantly less resources and being a significantly younger team. 
Noteworthy, we have published our research results and finding in similar type of scientific journals as 
the DMC. 
We recently participated in the evaluation of Finnish chemistry research that was conducted by the AF. 
The international evaluation panel has concluded its report (http://tinyurl.com/67cchtl) saying that “The 
unit should maintain its research direction and level of achievement, which is of high quality in an 
important societal area." 
 Ways to strengthen the focus and improve the quality of the RC’s research. 
RC’s strengths are: 1. The RC combines complementary expertise of two units within the Faculty. 2. Our 
methodologies can be applied to other types of projects beyond medicinal chemistry such as chemical 
biology, and for studying biochemical function and cellular localization of enzymes and receptors. 3. All 
our PI’s have spent >2 years in leading research groups abroad, and promote open collaborative 
scientific work. 4. None of the PI’s has been recruited in-house, the typical drawback wherein the faculty 
members are recruited among their own alumni. 
The quality of our research is likely to improve by the following actions: 1. Annual self-evaluation of 
scientific progress, productivity and quality by using the internationally recognized Dutch DMC as a 
reference unit. 2. Recruitment of more post-doctoral researchers (if suitable funds are available). 3. The 
EC-funded MAREX project will generate new scientific collaborations and research into bioactive marine 
compounds. 4. Locally, the Biocenter Finland network is likely to further stimulate collaborations with 
medical researchers. 
 
 
  How is doctoral training organised in the RC? Description of the RC’s principles for recruitment and 
selection of doctoral candidates, supervision of doctoral candidates, collaboration with faculties, 
departments/institutes, and potential graduate schools/doctoral programmes, good practises and 
quality assurance in doctoral training, and assuring good career perspectives for the doctoral 
candidates/fresh doctorates.  
Recruitment: The majority of the RC doctoral student positions are announced in the Recruitment web 
page of the University. The PI’s review the applications that are treated in equal manner during the 
evaluation and selection process. A completed MSc degree is the first criterion for the applicants of 
doctoral student positions. The other selection criteria are the scientific quality of a research plan, 
previous scientific achievements of the applicant and the probability that the candidate will successfully 
complete his/her doctoral studies within a reasonable time. Recruitment is based on the guidelines of 
the Ministry of Education and Culture, and participation of younger and female doctoral students is 
encouraged. The top candidates are interviewed by the PI’s. 
 
Supervision of doctoral candidates: The objective of supervision is to commit doctoral candidates to the 
completion of their PhD degree and to commit the University, Faculty and the RC to the provision of the 
necessary teaching, supervision and support. Special attention is paid to supervision at the initial stage 
of doctoral studies. Doctoral candidates are provided with orientation to doctoral studies and are 
guided in making good use of the available course offerings. Student integration into the scholarly 
community is also promoted. The Faculty Council has approved guidelines concerning the rights and 
duties of supervisors and doctoral students. When making supervision arrangements, the doctoral 
students and their supervisors are expected to study these guidelines (“Supervisory expectations and 
responsibilities”). 
2 PRACTISES AND QUALITY OF DOCTORAL TRAINING (MAX. 8800 CHARACTERS WITH SPACES) 
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The supervisor and doctoral student meet regularly to assess progress in research and doctoral studies. 
The supervision is more intense at the beginning of doctoral studies, while more responsibility is given 
to the doctoral student at later stages with aim of “generating” an independent and critically thinking 
scientist of him/her. All the research groups of the RC organize regular group meetings where the 
research-related issues are discussed. Doctoral students can make alteration to their study plan with 
supervisor´s approval. If a research plan changes drastically or if a supervisor is changed, the Research 
Affairs Committee of the Faculty should approve the development. The doctoral students themselves 
have responsibility for their progress and must inform their supervisor and the Faculty if their studies 
are considerably delayed for some reason (e.g. maternity/parental leave, work circumstances). 
Three instruments are used to guide the supervision of doctoral studies. First, the preliminary research 
plan is part of the application package when a person applies for the doctoral student position. The plan 
is based on the choice of a major subject at the start of the doctoral studies, and is drawn up with the 
supervisor’s assistance. Second, the personal study plan is based on the Faculty’s postgraduate 
application form, and doctoral students discuss their study plan (e.g. research schedule and content of 
studies, lecture and laboratory courses that support research) with their supervisor. Third, defence of 
the research proposal is required at 1–2 years after starting the doctoral studies. The doctoral students 
prepare the research plan and the supervisor comments on it before it is sent to the members of the 
evaluation board. The aim of the research plan defence is to evaluate how well a student can plan 
research, as well as to debate, defend and discuss the topics of his/her research. Essential and 
fundamental theoretical background of the research is also examined. Feedback from research plan 
defence is given to the doctoral student and his/her supervisors as a written report. 
 
Collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes: Our RC has direct links to the Graduate School in Pharmaceutical Research (GSPR), a 
national graduate school that was founded as collaboration between the University of Helsinki and the 
University of Eastern Finland (Kuopio) in 1998. Moreover, the current vice director of GSPR is the 
coordinator of our RC. GSPR is part of the FinPharmaNet network of Graduate Schools. It offers a multi-
disciplinary and well-organized doctoral education in pharmaceutical research. It includes several 
research groups and is a part of national and international pharmaceutical research network including 
connections with pharmaceutical companies. GSPR grants travel funds for doctoral students that wish to 
visit foreign collaborating laboratories and carry out part of their research abroad. Our RC also has one 
doctoral student in the National Doctoral Program in Informational and Structural Biology, and good 
contacts with the National Graduate School of Organic Chemistry and Chemical Biology. Our RC is also 
part of the Paul Ehrlich MedChem Euro-PhD Network, the aim of which is to foster education and 
research training of post-graduate students in medicinal chemistry in Europe. 
The RC has excellent contacts with the home faculty, Faculty of Pharmacy, as well as with other faculties 
and institutes in the Viikki Campus, and rest of the University of Helsinki. In particular, this includes the 
Faculties of Veterinary Medicine, Agriculture and Forestry, Science, Medicine, and the Institute of 
Biotechnology and the Neuroscience Centre. Moreover, the RC has an extensive domestic and 
international research network as described later. 
 
Good practises and quality assurance in doctoral training: The doctoral training in our RC is mainly based 
on the rules, regulations and recommendations of the University, Faculty and GSPR. Quality at the 
University means expedient activity and high-quality results which is illustrated tangibly in, for example, 
the quality handbooks of the Faculty and GSPR (the operating procedures of the Division of 
Pharmaceutical Chemistry and Centre for Drug Research are described in the Quality Manuals of the 
respective units). The following is a brief collection of “good practises” at our RC: 1. Faculty 
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Postgraduate Study Guide; 2. clear and instructional web pages of the GSPR; 3. regular research group 
meetings; 4. personal study plans of doctoral students; 5.defence of the research proposal. 
 
Assuring good career perspectives for the doctoral candidates/fresh doctorates: Our RC provides an 
excellent learning environment for postdoctoral fellows, postgraduate and undergraduate students. The 
variety of interdisciplinary pursuits with ambitious goals encompassed by our many projects ensures 
that they will gain expertise in a broad array of methodologies and techniques. Hence, they are well-
poised to succeed as independent and highly competent scientists, either in industry or academia. These 
possibilities increase the likelihood of benefiting society, both as a result of the practical and theoretical 
capabilities of our fresh doctorates and postdoctoral fellows, as well as due to their abilities to teach and 
lead others. Nearly all the candidates who obtained their PhD or MSc degrees during the evaluation 
period have found their current employment that corresponds or is complementary to their doctoral 
training. Finally, our RC is one of the very few training places for students in chemoinformatics in 
Finland. 
Our RC participated recently in the evaluation of the chemistry research in Finland 2005-9 by the 
Academy of Finland. The international evaluation panel concluded in their final report 
(http://tinyurl.com/67cchtl) that “The unit provides an excellent learning environment for postdoctoral 
fellows and postgraduate and undergraduate students.” 
 RC’s strengths and challenges related to the practises and quality of doctoral training, and the actions 
planned for their development. 
Strengths: (i) We have started to increase the exposure of undergraduate students to the scientific 
research in our laboratories by providing them a possibility and incentive to carry out part-time research 
work in the laboratory, alongside their regular studies. To this end we have established a course 
Laboratory Experience within a Research Group (3-5 cu). Four undergraduate students are currently 
involved in this activity in our RC. (ii) Our extensive national and international networks for doctoral 
training, as well as excellent scientific collaborators, are among the strengths of the RC. (iii) We have 
compiled a Postgraduate Handbook with good practises of doctoral training. 
 
Challenges: (i) Obtaining the PhD degree takes still too long a time (>4 years), mostly due to short-term 
or dispersed funding by the funding agencies. Another possible reason for this is the “unwritten” 
requirement to include 4 peer-reviewed articles in PhD theses of the University of Helsinki. (ii) Another 
challenge is to stimulate the RC doctoral students to carry out part of their research abroad. 
 
 
 Description of how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector).  
Our interactions with the society are primarily realized via our research and researchers training. The 
following is a description of our societal impact and its public visibility. 
First, we initiated negotiations among the Finnish medicinal chemistry community to join the European 
Federation of Medicinal Chemistry. As a result, Finland is now a full member of EFMC, whose objective is 
to advance the medicinal chemistry science by promoting cooperation, contacts and exchanges between 
European medicinal chemists. 
Second, we participate in collaborative research with industry and SMEs. Such projects have been 
funded by EC, Tekes, pharmaceutical industry and Forestcluster (Finnish Strategic Centre for Science, 
Technology and Innovation). Many patent applications have been filed already (n=8), and researchers 
from industry (n=2) have visited us to learn and adopt new techniques while doing research for their 
3 SOCIETAL IMPACT OF RESEARCH AND DOCTORAL TRAINING (MAX. 4400 CHARACTERS WITH SPACES) 
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PhD degrees. Our RC has also played an active role in creating new research programs, such as Drug-
2000 and IVIVRe, financed by the industry and Tekes. 
Third, we belong to the Drug Discovery and Chemical Biology program for translational research of 
Biocenter Finland. We aim to provide advice and resources for development of chemical biology and its 
applications. We coordinate chemical compound databases, make our compounds available for virtual 
chemical screening and provide tools & scientific expertise. 
Fourth, we carry out anti-doping, forensic and illicit drug research. 1. Our RC has participated in three 
World Anti-Doping Agency-funded projects and supplied the accredited doping control laboratories with 
reference substances worldwide (psychostimulant, steroid & antiestrogen metabolites). The reference 
substances enable reliable and legally defensible confirmation analysis of these drugs from the doping 
control samples. 2. Another WADA-supported research project was identification of the UGT enzymes 
that catalyze the glucuronidation of testosterone and epitestosterone, and clarification of genetic 
reasons that make testosterone and related steroids abuse by athletes from certain populations largely 
undetectable by the current approved method to test for such doping in major international sport 
competitions. Hence, our studies for WADA have contributed to curbing illicit athletes doping. 3. We 
have studied the glucuronidation of psilocin and identified UGTs that catalyze metabolic clearance of 
this hallucinogenic drug of abuse. This recent study is expected to facilitate forensic investigations of 
psilocin and related drugs. The extensive explorations we have done into drug glucuronidation will help 
to reduce adverse drug effects in humans, both by enabling more accurate dosing of individual drugs to 
individual patients, and by improving prevention of drug-drug interactions. Another societal 
contribution is a significant contribution to the quality and professionalism, in different aspects of 
medicinal chemistry and biotransformation, of employees in both pharmacies and in drug regulatory 
agencies in Finland. 
Fifth, RC is publicly visible. We have given popular lectures of medicinal chemistry research to students 
and teachers in the local schools. Our research has also been highlighted in newspapers, magazines and 
radio programs. 
 Ways to strengthen the societal impact of the RC’s research and doctoral training. 
In the long-term we can envisage that our basic research, discoveries, and inventions will benefit society 
and mankind by providing new hit and lead molecules. These, in turn, will be used for further 
development to achieve potent, efficient, safe and affordable drugs. In Europe and other parts of the 
world with high standard of living, diseases such as cancers are an increasing threat to public health. On 
the other hand, in developing countries, parasitic infectious diseases are an enormous health and 
economic challenge. Part of our research is focused on cancer (leukemias, prostate cancer) and tropical 
parasitic diseases (leishmaniasis). In the future, innovations based on our research could be available to 
combat these diseases. A concrete action to strengthen the RC’s societal impact is developing our 
doctoral training to yield even higher quality PhDs for society. Another option is to develop 
collaboration between the RC and the drug industry, e.g. by attracting researchers from companies to 
the RC to learn new methods. 
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 Description of the RC’s research collaborations and joint doctoral training activities and how the RC 
has promoted researcher mobility.  
The RC’s doctoral students belong either to Graduate School in Pharmaceutical Research or National 
Doctoral Program in Informational and Structural Biology. 
The RC’s research collaboration may be described at local, domestic and international levels. The local 
collaborators are within our home university. The most important collaborators in the Faculty of 
Pharmacy are: Centre for Drug Research (bioactivity screening), Pharmaceutical Chemistry (analytical 
techniques), Pharmaceutical Technology (transport) and Pharmacology & Toxicology (protein kinases). 
The key collaborators in Viikki Campus are Institute of Biotechnology (alphaviruses, NMR, protein 
structures), Neuroscience Center (tyrosine kinases), Faculty of Veterinary Medicine (orexin), and Faculty 
of Agriculture (terpenes). The major collaborators in Meilahti Campus are from the Faculty of Medicine 
(kallikreins). 
Other domestic collaborators are from the University of Eastern Finland (kallikreins), the Technical 
Research Centre of Finland (terpenes), the University of Tampere (inflammation), and from the Åbo 
Akademi (Chlamydia, structural bioinformatics). 
Our closest Nordic collaborators are University of Gothenburg (kallikreins) and University of 
Copenhagen (synthesis methods). Other international collaborators are Universite de Lyon, University of 
Birmingham, University of Geneva & University of Milano-Bicocca (protein kinases); Hebrew University 
of Jerusalem & Universidad Complutense de Madrid (Leishmania); University of Ljubljana and KU Leuven 
(marine compounds); EFPL (Mycobacteria); Technische Universität Chemnitz (small molecule X-ray) and 
Martin-Luther-Universität Halle-Saale (modeling); Tufts University, USA, University of Arkansas for 
Medical Sciences, USA, and the Flinders Medical Centre, Australia (different aspects of UGTs research). 
The RC is involved in the following FP6 or FP7 research projects of the EC: Protein Kinase Research, 
LIINTOP, FORESTSPECS, MAREX (see Ch. 2). The RC participates also the following COST networks: New 
drugs for neglected diseases & Combinatorial chemistry and the Paul Ehrlich MedChem Euro-PhD 
Network for doctoral training. 
Another way in which the RC is involved in international collaborations is examination and evaluation of 
PhD theses. We almost always employ international opponent for the public examination of PhD theses 
of our students, often also send the theses for pre-examination by internationally-known scientists in 
the respective fields, and act ourselves as pre-examiners and opponents for PhD theses in other 
countries. We participate actively in international scientific meetings, symposia and seminars and 
present our research there. 
 
How the RC has promoted researcher mobility? 
Two doctoral students of the RC have carried out part of their research abroad, in the Universities of 
Gothenburg and Copenhagen. One RC student takes part in the Medicinal Chemistry Euro-PhD Network. 
We have also attracted a number of international students and researchers at different levels, from 
undergraduate students for shorter periods (ERASMUS, COST) to those that do their postgraduate 
research in our laboratories, as well postdoctoral researchers. 
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 RC’s strengths and challenges related to research collaboration and researcher mobility, and the 
actions planned for their development. 
Strengths: RC is involved in excellent local [Viikki], domestic [Meilahti, Kumpula, VTT, Finnish universities 
and institutes], and in international networks (EU, COST, ERASMUS) and collaborations with high 
scientific/technological level. RC has gained strong management and organizational skills as co-
ordinators of large international research consortia. 
The evaluation panel of Chemistry Research in Finland (2005-9) stated of our RC: “The unit has much 
active collaboration within UH, as well as with other Finnish universities and institutes. Many industrial 
collaborations are effective through Tekes projects. The unit has succeeded in internationalisation, as 
evidenced by the presence of postdoctoral researchers and postgraduate students from abroad.” 
Challenges: Researcher mobility from RC to the foreign research institutes and universities could still be 
improved considerably. We hope that participation in EC-funded projects as well as the current COST 
and Euro-PhD programs would facilitate the international mobility from our RC. 
 
 
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties).  
The RC has an experienced, qualified and motivated personnel, good instrumentation and external 
funding. Its scientists come from two administrative units of the Faculty: Division of Pharmaceutical 
Chemistry and Centre for Drug Research. The RC has infrastructure of both units at its disposal. The 
general technical and administrative infrastructure of UH is excellent (Helsinki University Library, 
Research Services, Information Technology, Personnel and Legal Services and Support for Teaching). 
However, the Finances of the University is unfortunately lacking behind as the tools provided for 
financial management of projects and research units are of mediocre quality. Moreover, its level of 
assistance and service has plenty of room for improvement. 
Our biochemical, medicinal chemistry and synthesis laboratories are relatively well-equipped: 300 MHz 
Varian NMR spectrometer; Waters HPLC/MS instruments for both analytical and preparative work; 
Hewlett-Packard GC/MS (since 1988!); Bruker FTIR spectrometer equipped with an ATR device and a 
microscope; Biotage microwave synthesizer and parallel chromatography system; parallel solid-phase 
synthesizers for the hit/lead optimization. One of our RC groups has introduced DNA technologies and 
gene expression to the Faculty and maintains and uses the infrastructure to carry out gene cloning and 
expression as well as protein purification and analyses by state-of-the-art methods. For computational 
modeling started in 2008, a modern computer network and the necessary software obtained from 
academic licenses by the Finnish Center for Scientific Computing. 
The RC has an access to many facilities in Viikki Campus via Instrument Centre, Core Facilities and other 
co-operation laboratories. Although there are many instruments available, some of them are very old 
and there is an urgent need for high-performance instruments for RC’s research (a high-field NMR 
instrument and HPLC-MS for routine use). 
Administrative duties: RC Members have had many positions of university and faculty administration: 
JYK: Head of the Division of the Pharmaceutical Chemistry; vice-dean in charge of research affairs; 
member: faculty council, board of Viikki Science Library, board of DDTC, planning committee, chemical 
management working group; chair of student selection committee; EW: member: committee for the 
academic affairs, student selection committee; vice-member: planning committee, advisory board of 
Viikki Campus Library; MF: member of the committee for research affairs. Finally, several RC researchers 
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were appointed as members of various permanent and ad hoc committees of the Faculty during 2005-
10. 
Educational duties: Our RC is responsible for BSc, MSc and PhD level lecture and practical courses (54 
cu) in the Faculty (medicinal, pharmaceutical and organic chemistry; drug metabolism, computer-aided 
drug discovery; molecular and cell biology, biochemistry). The RC members supervise a relatively large 
number of under and postgraduate studies and are also involved in the supervision of postgraduate 
studies in other units of UH and domestic universities. The RC also provides the undergraduates of 
Faculty of Biosciences and Helsinki Region Biotechnology Educational Program with extensive organic 
chemistry course package (9 cu). 
 RC’s strengths and challenges related to operational conditions, and the actions planned for their 
development. 
Strenghts: The RC has good infrastructure with relatively modern instrumentation. Our RC has an 
experienced, qualified and dedicated personnel and good external funding. 
 
Challenges: Mechanisms of purchasing expensive research instruments and equipment in a coordinated 
and fair manner as well as of financing instrument repairs both in the Faculty and University level are 
insufficient. The most urgent research instruments needed are the new high-field NMR spectrometer 
and a robust routine HPLC-MS for the routine use of RC. In addition, lack of personnel responsible for 
instrument maintenance, routine laboratory operations and computational infrastructure support 
increases the workload of the RC members. Computational modelling would greatly benefit from an on-
site IT specialist, available in other Finnish universities, such as UEF and ÅA. 
 
Finally one of our major endemic/generic challenges is the continuously increasing workload in terms of 
faculty and university bureaucracy and related administration, which seriously depletes human 
resources for research and doctoral training. 
 
 
 
 Description of the execution and processes of leadership in the RC, how the management-related 
responsibilities and roles are distributed in the RC and how the leadership- and management-related 
processes support high quality research, collaboration between principal investigators and other 
researchers in the RC, the RC’s research focus and strengthening of the RC’s know-how.  
The RC combines the complementary expertise of two units of the Faculty: Division of Pharmaceutical 
Chemistry (DPC) and Centre for Drug Research (CDR). Principal investigators Erik Wallén and Jari Yli-
Kauhaluoma are from the Medicinal Chemistry research group of the DPC. Principal investigators Henri 
Xhaard and Moshe Finel represent CDR and its Computational Drug Discovery group and the Molecular 
and Biochemical Pharmacology group. The four principal investigators are responsible for research 
strategy of the RC, implementation of the objectives of their research projects and the respective plans 
of actions. The major principles of RC leadership are appreciation, interaction and trust at all levels. 
These help us to create an open and innovative research environment and an excellent working spirit as 
well as to encourage our doctoral students to present their own ideas. 
In general RC adheres to the Strategic Plan for the University and in particular to the research strategies 
of DPC and CDR. The main strategic objective is to maintain high standards and a high profile of the RC 
research and its further development in the long term. As a tool of research management we use 
regular self-assessments and “benchmarking” by monitoring our key figures of scientific productivity 
and quality and comparing them against those of an internationally established research unit, the 
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Leiden/Amsterdam Center for Drug Research. We feel that self-assessments like this help us to maintain 
high standards and a high profile of research. In fact, the report of an International Evaluation of 
Chemistry Research in Finland 2005-9 by the Academy of Finland concluded of our RC that “The unit 
should maintain its research direction and level of achievement, which is of high quality in an important 
societal area.” 
Our RC attempts to establish a clear connection between strategic objectives of the University, DPC & 
CDR and various operative level practises especially by regular discussions about the strategic aims with 
the members of RC and divisions of the Faculty. For example, all the RC research teams have regular bi- 
or triweekly group meetings for the discussions dealing with progress of research and related 
administrative issues. The respective administrative units (DPC, CDR) have their own meetings for the 
discussions about the research strategies of the units. Moreover, the Lammi Research Seminar of the 
Faculty, organized annually since 2001, has become a natural forum for discussions about science, 
research, doctoral training and research strategies of the research groups and Faculty. 
The strengthening of know-how of the RC members takes place first and foremost via our research 
projects and participation to the domestic and international research programmes and networks. The 
RC researchers attend regularly domestic and international scientific meetings, conferences, seminars 
and symposia. Our RC openly supports these activities. 
Finally we actively support the diversity in our RC. Despite there being no female PIs in our RC, 32% 
(n=11) from the scientists contributing to the RC are females, at different stages of their careers, and at 
different stages of their private and family life. The proportion of foreign scholars and students is 38% 
(n=13) in our RC. 
 RC’s strengths and challenges related to leadership and management, and the actions planned for 
developing the processes. 
Our strengths are in a successful maintenance of research direction and level of achievement. Thanks to 
experienced, qualified and dedicated personnel we have maintained excellent working spirit and kept 
research aims clear. Our research projects also form a synergistic entity. 
Challenges relate to the fact that RC teams belong to two separate administrative units. Despite clear 
scientific foci of RC teams, creation of a unified and coherent research strategy for the RC may be 
hampered as a whole. Teaching obligations of the units also differ significantly from each other. The CDR 
members use a maximum 5% of the annual 1600-h workload for teaching, while the corresponding 
figures in DPC range from 5 to as high as 30%. 
Finally we feel that continuously increasing workload in the faculty and university bureaucracy, 
administration and other secondary actions depletes resources of research and doctoral training. A 
concrete challenge is to prioritize the administrative actions and execute only the most important ones, 
i.e. those that promote high quality research and doctoral training. 
 
 
 
 Listing of the RCs external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
- the administrator of the funding is/has been the University of Helsinki 
 
 Academy of Finland (AF) - total amount of funding (in euros) AF has decided to allocate to the RC 
members during 1.1.2005-31.12.2010: 1110000 
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 Finnish Funding Agency for Technology and Innovation (TEKES) - total amount of funding (in euros) 
TEKES has decided to allocate to the RC members during 1.1.2005-31.12.2010: 670000 
 
 European Union (EU) - total amount of funding (in euros) EU has decided to allocate to the RC members 
during 1.1.2005-31.12.2010: 1580000 
 
 European Research Council (ERC) - total amount of funding (in euros) ERC has decided to allocate to the 
RC members during 1.1.2005-31.12.2010: 0 
 
 International and national foundations – names of international and national foundations which have 
decided to allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their 
funding (in euros).  
- names of the foundations: Sigrid Juselius Foundation (268500 eur), Center for International 
Mobility (34480 eur), Walter och Lisi Wahls stiftelse för naturvetenskaplig forskning (10000 eur), 
Research Foundation for Clinical Chemistry (10000 eur), Päivikki & Sakari Sohlberg Foundation 
(70000 eur), Foundation for Research of Natural Resources in Finland (122000 eur), Marjatta ja 
Eino Kollin Säätiö (180000 eur), University of Helsinki research foundation (22000 eur)  
- total amount of funding (in euros) from the above-mentioned foundations: 720000 
 
 Other international funding - names of other international funding organizations which have decided to 
allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in 
euros). 
- names of the funding organizations: World Anti-Doping Agency, WADA (61000 eur, 166500 eur, 
81600 eur) 
- total amount of funding (in euros) from the above-mentioned funding organizations: 310000 
 
 Other national funding (incl. EVO funding and Ministry of Education and Culture funded doctoral 
programme positions) - names of other national funding organizations which have decided to allocate 
funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in euros). 
- names of the funding organizations: Forestcluster Ltd. (160000 eur), Biocenter Finland (28000 
eur), Ministry of Education and Culture (310000 eur) 
- total amount of funding (in euros) from the above-mentioned funding organizations: 500000 
 
 
 
 Description of the RC’s future perspectives in respect to research and doctoral training. 
The cornerstone of our research strategy is excellent research and educational results that have been 
achieved in the research areas, where we are already at international high level or soon approaching it 
(please see Chapter 1). During 2011-2013 our RC will focus to medicinal chemistry and biochemistry 
research of the following themes: (i) medicinal chemistry of cancer chemotherapy (protein kinase 
research and peptidomimetics of kallikreins), (ii) new antibiotics and antivirals against intracellular 
pathogens (Leishmania sp., Chlamydia pneumoniae, Alphavirus), (iii) metabolism of drugs and other 
xenobiotics and (iv) medicinal chemistry of G protein-coupled receptors (orexin, alpha-2 adrenergic 
receptors). We intend to strengthen these research areas, integrate them better with each other, and 
pay careful attention to the selection of possible new research areas to. New research areas for our RC 
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are expected to support the existing work or they should be so revolutionary in nature so that we will 
focus all our efforts to them, if we are convinced that they are groundbreaking areas. 
One of our aims is to increase research with considerable risk that is based on original basic research of 
our RC. We hope to have the means to support long-term basic, original and high quality research, as we 
believe that it only is capable of yielding the best results in the future. Our aim is also (i) to continue 
doing multidisciplinary research by recruiting scientists with various and complementary backgrounds in 
the fields such as chemistry, pharmaceutical sciences, biology and biochemistry, (ii) to continue working 
with our current collaborators, (iii) to continue finding new domestic and international collaborators, 
who can help us to reach the highest international level in our selected research areas, and (iv) to 
continue publishing our research results in high quality journals of the field. 
There are several actions which we will do to support these strategic aims. We will place more emphasis 
on recruiting new and suitable staff. We will aim at (i) employing more post-doctoral researchers in our 
RC, (ii) supporting academic careers of young promising researchers, (iii) continuing and increasing high-
quality domestic and international collaborations, and (iv) investing in education of postgraduate and 
undergraduate students. We are planning to recruit the best undergraduate students by continuing to 
provide them with a possibility to join our multidisciplinary research groups already at early stages of 
their studies in the Faculty of Pharmacy. In addition, improvement of research infrastructure is an 
important supporting action. Currently, there is a need for improved instrumentation (e.g. a high-field 
NMR instrument and a robust HPLC-MS). 
We promote advancement of science by encouraging our researchers to present their own ideas, 
promoting co-operation with national and international research groups, supporting international 
researcher exchange, and most importantly participating actively in European and global research 
networks. The co-operation with industry and private laboratories is an essential part of the 
implementation of the research aims for the benefit of society and mankind. 
The well-being of our personnel is taken care by open management policy and by maintaining 
innovative and co-operative working atmosphere in our RC. It is also important to be visible in scientific 
meetings and organizations, for example by organizing international researcher meetings, courses, 
seminars, workshops etc., as well as in society in general to point out the significance of medicinal 
chemistry and biochemistry in the drug discovery and development process and to be able to make an 
effort to ensure long-term funding to support basic research, recruitment of the best scientists and 
improvement of infrastructure. We will also take an active role in popularizing our research to the larger 
audience. 
 
 
 
After the preparatory discussions and planning meeting of the MedChemBio RC evaluation, JYK 
prepared the first draft of the stage 2 materials and sent it to other principal investigators of the RC 
(EW, MF, HX) for comments and further writing and editing. The resulting 2nd draft was circulated for 
additional changes, comments and proofreading. The final third version of the stage 2 material was 
accepted as a final submission version of the evaluation package. 
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1 Analysis of publications 
 
- Associated person is one of Moshe Finel ,  Erik Wallen ,  Henri Xhaard ,  Jari Yli-Kauhaluoma 
, Ingo Aumuller ,  Kirsi Harju ,  , Paula Kiuru , 
 Liisa Laakkonen , Mohanathas Rajaratnam ,  Leslie Regad , 
 Swapan Kumar Samanta, Andrew Charles Tadd ,  Sami Aleksi Alakurtti , Martti Alkio , 
 Ingo Bichlmaier ,  ,  Gustav Boije af Gennäs ,  Raisa Haavikko 
,  Sanna Kaivosaari ,  Leena Keurulainen , Alexandros Kiriazis , 
 Mika Kurkela ,  Tuomo Kaarlo Erik Leikoski ,  Nenad Manevski , 
 Kristian Meinander ,  Antti Siiskonen ,  Nina Sneitz ,  
Taina Sten ,  Michal Andezej Stepniewski ,  Mikko Vahermo ,  Gloria Wissel , 
 Hongbo Zhang ,  Yuezhou Zhang , 
 
Publication year 
Publication type 2005 2006 2007 2008 2009 2010 
Total Count 2005 - 
2010 
A1 Refereed journal article 20 18 21 21 21 22 123 
A2 Review in scientific journal 2 1  1   4 
A4 Article in conference publication (refereed) 2   2 3 1 8 
B1 Unrefereed journal article  1 1    2 
B3 Unrefereed article in conference proceedings 1      1 
C2 Edited book, compilation, conference proceeding or special issue of 
journal 
  1    1 
D2 Article in professional hand or guide book or in a professional data 
system, or text book material 
   1   1 
H1 Patents      2 2 
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2 Listing of publications 
 
 
A1 Refereed journal article 
2005 
Alonen, A, Aitio, O, Hakala, K, Luukkanen, L, Finel, M, Kostiainen, R 2005, 'Biosynthesis of dobutamine monoglucuronides and 
glucuronidation of dobutamine by recombinant human UDP-glucuronosyltransferases',  Drug Metabolism and Disposition, vol 33, no. 
5, pp. 657-663. 
Finel, M, Gardner-Stephen, D, Bratton, S, Mackenzie, PI, Radominska-Pandya, A 2005, 'Human UDP-glucuronosyltransferase 1A5: 
identification, expression, and activity', Journal of Pharmacology and Experimental Therapeutics, vol 315, no. 3, pp. 1143-1149. 
Hakala, KS, Suchanova, B, Luukkanen, L, Ketola, RA, Finel, M, Kostiainen, R 2005, 'Rapid simultaneous determination of metabolic 
clearance of multiple compounds catalyzed in vitro by recombinant human UDP-glucuronosyltransferases',  Analytical Biochemistry, 
vol 341, no. 1, pp. 105-112. 
Jarho, E, Wallen, EAA, Christiaans, J, Forsberg, M, Venäläinen, J, Männistö, PT, Gynther, J, Poso, A 2005, 'Dicarboxylic acid azacycle 
L-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the 
enzyme-inhibitor interactions', Journal of Medicinal Chemistry, vol 48, no. 15, pp. 4772-4782. 
Kiuru, PS, Wähälä, K 2005, 'Microwave-assisted synthesis of deuterium labeled estrogen fatty acid esters',  Steroids, vol 71, no. 1, pp. 
54-60. 
Kärkkäinen, J, Forsström, T, Tornaeus, J, Wähälä, K, Kiuru, P, Honkanen, A, Stenman, U, Turpeinen, U, Hesso, A  2005, 'Potentially 
hallucinogenic 5-hydroxytrypramine receptor ligands bufotenine and dimethyltryptamine in blood and tissues', Scandinavian Journal of 
Clinical & Laboratory Investigation, vol 65, no. 3, pp. 189-199. 
Leikoski, T, Kaunisto, J, Alkio, M, Aaltonen, O, Yli-Kauhaluoma, J 2005, 'Unusual Nazarov cyclization in near-critical water', Organic 
Process Research and Development, vol 9, no. 5, pp. 629-633. 
Luukkanen, L, Taskinen, J, Kurkela, M, Kostiainen, R, Hirvonen, J, Finel, M 2005, 'Kinetic characterization of the 1A subfamily of 
recombinant human UDP-glucuronosyltransferases', Drug Metabolism and Disposition, vol 33, no. 7, pp. 1017-1026. 
Pakkanen, J, Nousiainen, H, Yli-Kauhaluoma, J, Kylänlahti, I, Möykkynen, T, Korpi, ER, Peng, J, Lukas, R, Ahtee, L, Tuominen, R 2005, 
'Methadone increases intracellular calcium in SH-SY5Y and SH-EP1-h[alpha]7 cells by activating neuronal nicotinic acetylcholine 
receptors', Journal of Neurochemistry, vol 94, no. 5, pp. 1329-1341. 
Rein, M, Ollilainen, V, Vahermo, M, Yli-Kauhaluoma, J, Heinonen, M 2005, 'Identification of novel pyranoanthocyanins in berry juices', 
European Food Research and Technology, vol 220, no. 3-4, pp. 239-244. 
Salo, PK, Salomies, H, Harju, K, Ketola, RA, Kotiaho, T, Yli-Kauhaluoma, J, Kostiainen, R 2005, 'Analysis of small molecules by ultra 
thin-layer chromatography-atmospheric pressure matrix-assisted laser desorption/ionization mass spectrometry',  Journal of the 
American Society for Mass Spectrometry, vol 16, no. 6, pp. 906-915. 
Samanta, S, Yli-Kauhaluoma, J 2005, 'Polymer-supported 1,3-Oxazolium-5-olates: synthesis of 1,2,4-Triazoles',  Journal of 
Combinatorial Chemistry, vol 7, no. 1, pp. 142-146. 
Samanta, S, Kylänlahti, I, Yli-Kauhaluoma, J 2005, 'Microwave-assisted synthesis of imidazoles: Reaction of p-toluenesulfonylmethyl 
isocyanide and polymer-bound imines', Bioorganic & Medicinal Chemistry Letters, vol 15, no. 16, pp. 3717-3719. 
Sandler, C, Ekokoski, E, Lindstedt, KA, Vainio, PJ, Finel, M, Sorsa, T, Kovanen, PT, Golub, L, Eklund, KK, Eklund, K 2005, 'Chemically 
modified tetracycline (CMT)-3 inhibits histamine release and cytokine production in mast cells: possible involvement of protein kinase C',  
Inflammation Research, vol 54, pp. 304-312. 
Sen, S, Jaakola, V, Pirilä, P, Finel, M, Goldman, A 2005, 'Functional studies with membrane-bound and detergent-solubilized alpha(2)-
adrenergic receptors expressed in Sf9 cells', Biochimica et Biophysica Acta. Biomembranes, vol 1712, no. 1, pp. 62-70. 
Sipilä, J, Nurmi, H, Kaukonen, AM, Hirvonen, J, Taskinen, J, Yli-Kauhaluoma, J 2005, 'A modification of the Hammett equation for 
predicting ionisation constants of p-vinyl phenols', European Journal of Pharmaceutical Sciences, vol 25, no. 4-5, pp. 417-425. 
Toker, J, Tremblay, M, Yli-Kauhaluoma, J, Wentworth, A, Zhou, B, Wentworth, P, Janda, K 2005, 'Exploring the scope of the 29G12 
antibody catalyzed 1,3-dipolar cycloaddition reaction', Journal of Organic Chemistry, vol 70, no. 20, pp. 7810-7815. 
Venäläinen, JI, Wallen, EAA, Poso, A, García-Horsman, JA, Männistö, P 2005, 'Synthesis and characterization of the novel fluorescent 
prolyl oligopeptidase inhibitor 4-fluoresceinthiocarbamoyl-6-aminocaproyl-L-prolyl-2(S)-(hydroxy-acetyl)pyrrolidine',  Journal of 
Medicinal Chemistry, vol 48, no. 23, pp. 7093-7095. 
Wikström, M, Ribacka, C, Molin, M, Laakkonen, L, Verkhovsky, M, Puustinen, A 2005, 'Gating of proton and water transfer in the 
respiratory enzyme cytochrome c oxidase', Proceedings of the National Academy of Sciences of the United States of America, vol 
102, no. 30, pp. 10478-10481. 
 
 
MEDCHEMBIO/Yli-Kauhaluoma 
 
3 
 
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC TUHAT COMPILATIONS OF PUBLICATIONS DATA 2005-2010 
 
 
Yli-Kauhaluoma, J, Laine, A, Ratilainen, J, Karjalainen, A 2005, 'Synthesis of benzobicyclo[2.2.1]heptylimidazoles as conformationally 
constrained adrenergic receptor antagonists', Heterocycles, vol 65, no. 11, pp. 2783-2790 . 
2006 
Aumuller, I, Lindhorst, T 2006, 'Chromophore-supported purification in parallel synthesis', European Journal of Organic Chemistry. 
Bichlmaier, I, Siiskonen, A, Finel, M, Yli-Kauhaluoma, J 2006, 'Stereochemical sensitivity of the human UDP-glucuronosyltransferases 
2B7 and 2B17', Journal of Medicinal Chemistry, vol 49, no. 5, pp. 1818-1827. 
Bichlmaier, I, Siiskonen, A, Kurkela, M, Finel, M, Yli-Kauhaluoma, J 2006, 'Chiral distinction between the enantiomers of bicyclic 
alcohols by UDP-glucuronosyltransferases 2B7 and 2B17', Biological Chemistry, vol 387, no. 4, pp. 407-416. 
Harju, K, Kylänlahti, I, Paananen, T, Polamo, M, Nielsen, J, Yli-Kauhaluoma, J 2006, 'Solid-phase synthesis of pyrazolopyridines from 
polymer-bound alkyne and azomethine imines', Journal of Combinatorial Chemistry, vol 8, no. 3, pp. 344-349. 
Jarho, E, Venäläinen, J, Juntunen, J, Yli-kokko, AL, Vepsäläinen, J, Christiaans, J, Forsberg, M, Järvinen, T, Männistö, PT, Wallen, 
EAA 2006, 'An introduction of a pyridine group into the structure of prolyl oligopeptidase inhibitors',  Bioorganic & Medicinal Chemistry 
Letters, vol 16, no. 21, pp. 5590-5593. 
Kervinen, M, Hinttala, R, Helander, H, Kurki, SS, Uusimaa, J, Finel, M, Majamaa, K, Hassinen, I  2006, 'The MELAS mutations 3946 and 
3949 perturb the critical structure in a conserved loop of the ND1 subunit of mitochondrial complex I',  Human Molecular Genetics, vol 
15, no. 17, pp. 2543-2552. 
Kiviranta, PH, Leppanen, J, Kyrylenko, S, Salo, HS, Lahtela-Kakkonen, M, Tervo, AJ, Wittekindt, C, Suuronen, T, Kuusisto, E, Jarvinen, 
T, Salminen, A, Poso, A, Wallen, EAA 2006, 'N,N '-bisbenzylidenebenzene-1,4-diamines and N,N '-bisbenzylidenenaphthalene-1,4-
diamines as sirtuin type 2 (SIRT2) inhibitors', Journal of Medicinal Chemistry, vol 49, pp. 7907-7911. 
Kreander, K, Kurkela, M, Siiskonen, A, Vuorela, P, Tammela, P 2006, 'Identification of COMT and ErmC inhibitors by using a microplate 
assay in combination with library focusing by virtual screening', Pharmazie, vol 61, no. 3, pp. 247-248. 
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ring substitution', Tetrahedron Letters, vol 51, no. 4, pp. 714-716. 
Haiko, J, Laakkonen, L, Juuti, KM, Kalkkinen, N, Korhonen, T 2010, 'The Omptins of Yersinia pestis and Salmonella enterica Cleave the 
Reactive Center Loop of Plasminogen Activator Inhibitor 1', Journal of Bacteriology, vol 192, no. 18, pp. 4553-4561. 
Itaaho, K, Laakkonen, L, Finel, M 2010, 'How Many and Which Amino Acids Are Responsible for the Large Activity Differences between 
the Highly Homologous UDP-Glucuronosyltransferases (UGT) 1A9 and UGT1A10?', Drug Metabolism and Disposition, vol 38, no. 4, 
pp. 687-696. 
Keurulainen, L, Salin, O, Siiskonen, A, Kern, JM, Alvesalo, JKO, Kiuru, P, Maass, M, Yli-Kauhaluoma, J, Vuorela, P  2010, 'Design and 
Synthesis of 2-Arylbenzimidazoles and Evaluation of Their Inhibitory Effect against Chlamydia pneumoniae.',  Journal of Medicinal 
Chemistry, vol 53, no. 21, pp. 7664-7674. 
Laakkonen, L, Finel, M 2010, 'A Molecular Model of the Human UDP-Glucuronosyltransferase 1A1, Its Membrane Orientation, and the 
Interactions between Different Parts of the Enzyme', Molecular Pharmacology, vol 77, no. 6, pp. 931-939. 
Lehtonen, P, Sten, T, Aitio, OMA, Kurkela, M, Vuorensola, K, Finel, M, Kostiainen, R  2010, 'Glucuronidation of Racemic O-
desmethyltramadol, the Active Metabolite of Tramadol', European Journal of Pharmaceutical Sciences, vol 41, no. 3/4, pp. 523-530. 
Leikoski, T, Kallonen, S, Yli-Kauhaluoma, JT  2010, 'The Sonogashira Coupling of Polymer-Supported Propargylamine with Aryl Iodides',  
Helvetica Chimica Acta, vol 93, no. 1, pp. 39-47. 
Manevski, N, Kurkela, M, Hoglund, C, Mauriala, T, Court, MH, Yli-Kauhaluoma, JT, Finel, M 2010, 'Glucuronidation of Psilocin and 4-
Hydroxyindole by the Human UDP-Glucuronosyltransferases', Drug Metabolism and Disposition, vol 38, no. 3, pp. 386-395. 
Pakkala, M, Weisell, J, Hekim, C, Vepsalainen, J, Wallen, EAA, Stenman, UH, Koistinen, HK, Narvanen, A 2010, 'Mimetics of the 
disulfide bridge between the N- and C-terminal cysteines of the KLK3-stimulating peptide B-2', Amino Acids, vol 39, pp. 233-242. 
Riihimaki-Lampen, LH, Vainio, MJ, Vahermo, M, Pohjala, LL, Heikura, JMS, Valkonen, KH, Virtanen, VT, Yli-Kauhaluoma, JT, Vuorela, 
PM 2010, 'The Binding of Synthetic Retinoids to Lipocalin beta-Lactoglobulins', Journal of Medicinal Chemistry, vol 53, no. 1, pp. 514-
518. 
Salin, O, Alakurtti, SA, Pohjala, L, Siiskonen, A, Maass, V, Maass, M, Yli-Kauhaluoma, J, Vuorela, P 2010, 'Inhibitory effect of the 
natural product betulin and its derivatives against the intracellular bacterium Chlamydia pneumoniae', Biochemical Pharmacology, vol 
80, no. 8, pp. 1141-1151. 
Siissalo, S, Laine, L, Tolonen, A, Kaukonen, AM, Finel, M, Hirvonen, J 2010, 'Caco-2 cell monolayers as a tool to study simultaneous 
phase II metabolism and metabolite efflux of indomethacin, paracetamol and 1-naphthol', International Journal of Pharmaceutics, vol 
383, no. 1-2, pp. 24-29. 
Sneitz, N, Bakker, CT, de Knegt, RJ, Halley, DJJ, Finel, M, Bosma, PJ 2010, 'Crigler-Naijar Syndrome in The Netherlands: Identification 
of Four Novel UGT1A1 Alleles, Genotype-Phenotype Correlation, and Functional Analysis of 10 Missense Mutants', Human Mutation, 
vol 31, no. 1, pp. 52-59. 
Sun, X(, Rajaratnam, M, Fowler, P(, Zhang, G( 2010, 'Extraction and characterisation of hemicelluloses from maize stem',  
Phytochemical Analysis, vol 21, no. 5, pp. 406-415. 
Zhang, YZ, Zhang, GC, He, Z, Sun, XF, Rajaratnam, M 2010, 'Visualization Study of Solid Poly (Ester-Amine Salt) Precursor Foaming 
Process', Cellular Polymers, vol 29, no. 1, pp. 45-57. 
A2 Review in scientific journal 
2005 
Harju, K, Yli-Kauhaluoma, J 2005, 'Recent advances in 1,3-dipolar cycloaddition reactions on solid supports', Molecular diversity, vol 
9, no. 1-3, pp. 187-207. 
 
 
MEDCHEMBIO/Yli-Kauhaluoma 
 
8 
 
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC TUHAT COMPILATIONS OF PUBLICATIONS DATA 2005-2010 
 
 
Yli-Kauhaluoma, J 2005, 'Kiinteäfaasisynteesi lääkkeenkeksimisen työkaluna', Dosis, vol 21, no. 1, pp. 42-50. 
2006 
Alakurtti, S, Mäkelä, T, Koskimies, S, Yli-Kauhaluoma, J 2006, 'Pharmacological properties of the ubiquitous natural product betulin', 
European Journal of Pharmaceutical Sciences, vol 29, no. 1, pp. 1-13. 
2008 
Finel, M, Kurkela, M 2008, 'The UDP-glucuronosyltransferases as oligomeric enzymes',  Current Drug Metabolism, vol 9, no. 1, pp. 70-
76. 
A4 Article in conference publication (refereed) 
2005 
Alonen, A, Finel, M, Kostiainen, R  2005, Screening of recombinant human UGTs responsible for glucuronidation of losartan, 
zolarsartan, and candesartan,, Drug Metabolism Reviews 37 Supplement 1 INFORMA HEALTHCARE. 
Sten, T, Qvisen, S, Kostiainen, R, Finel, M 2005, Stereoselective propranolol glucuronidation by human uridine-5'-
diphosphoglucuronosyltransferase recombinant enzymes,, Drug Metabolism Reviews 37 Supplement 1 INFORMA HEALTHCARE. 
2008 
Mirza, S, Miroshnyk, I, Alakurtti, SA, Yli-Kauhaluoma, J, Heinämäki, J, Yliruusi, J 2008, Polymorph screening: effect of solvent on phase 
transformation behavior of betulin,, Paper presented at American Association of Pharmaceutical Scientists (AAPS) Annual 
Meeting and Exposition, Atlanta, United States. 16. - 20. November, 2008. AAPS Journal 10 S2 SPRINGER NEW YORK LLC. 
Vahermo, M, Leinonen, A, Suominen, T, Kuuranne, T, Yli-Kauhaluoma, J 2008, 'Synthesis of mesocarb metabolites as reference 
compounds for doping analytics', in Proceedings of the Manfred Donike Workshop, 26th Cologne Workshop on Dope Analysis, 
pp. 317-321 Recent advances in doping analysis. 
2009 
Alakurtti, SA, Sacerdoti-Sierra, N, Pohjala, L, Jaffe, CL, Tammela, P, Yli-Kauhaluoma, J 2009, 'Pharmaceutical Applications of Birch 
Bark Extractive Betulin', in Science and technology of biomasses: advances and challenges (from forest and agricultural 
biomasses to high added value products, processes and materials), pp. 165-168. 
Sten, T, Bichlmaier, I, Kuuranne, T, Leinonen, A, Yli-Kauhaluoma, J, Finel, M 2009, 'Genetic Variability and Urinary 
Testosterone/Epitestosterone Ratio', in  Proceedings of the Manfred Donike Workshop, pp. 91-92 Recent advances in doping 
analysis, no. 17. 
Vahermo, M, Leinonen, A, Suominen, T, Kolmonen, M, Kuuranne, T, Yli-Kauhaluoma, J 2009, 'Synthesis of 17-Dihydroexemestane as a 
Reference Compound in Doping Control', in Proceedings of the Manfred Donike Workshop, pp. 327-330 Recent advances in 
doping analysis, no. 17. 
2010 
Mirza, S, Miroshnyk, I, Mohammadi , G, Alakurtti, SA, Hussain , M, Yli-Kauhaluoma, J, Urtti, A 2010, Electrospinning platform for 
fabrication of monodispersed nanoparticles for pharmaceutical applications,, Paper presented at 2010 FIP Pharmaceutical Sciences 
World Congress, New Orleans, United States. 14. - 18. November, 2010. AAPS Journal 12 S2 SPRINGER NEW YORK LLC. 
B1 Unrefereed journal article 
2006 
Yli-Kauhaluoma, J, Sivonen, K, Tuominen, RK 2006, 'Protein kinase research in the University of Helsinki', Dosis, vol 22, no. 2, pp. 152-
7. 
2007 
Lemberg, K, Korpi, E, Siiskonen, A, Yli-Kauhaluoma, J, Kontinen, VK, Viljakka, K, Kalso, E, Korpi, ER 2007, 'Oxycodone's mechanism 
of action and potency differences after spinal and systemic routes of administration: [reply]',  Anesthesiology, vol 106, no. 5, pp. 1064-
1065. 
B3 Unrefereed article in conference proceedings 
2005 
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Wähälä, K, Kiuru, P, Leppälä, E, Pohjoispää, M, Parikka, K, Raffaelli, B 2005, Controlled Polydeuteration of Estrogenic Compounds,, 
Paper presented at Workshop of the Central European Division e.V. of the International Isotope Society, Bad Soden , Germany. 
16. - 17. June, 2005. Journal of Labelled Compounds & Radiopharmaceuticals 49 JOHN/WILEY & SONS LTD.. 
C2 Edited book, compilation, conference proceeding or special issue of journal 
2007 
Yli-Kauhaluoma, J (ed.) 2007, The Taskinen Symposium on Drug Design and Metabolism: Faculty of Pharmacy, University of Helsinki 
August 17.18, 2007, Helsingin yliopisto, farmasian tiedekunta, Helsinki. 
D2 Article in professional hand or guide book or in a professional data system, or text book 
material 
2008 
Aumüller, I, Yli-Kauhaluoma, J 2008, 'The preferred conformations of heptafulvenes are determined by various factors', in A Sillanpää et 
al. (ed.), CSC report on computational science inFinland 2006-2007, CSC - Scientific Computing Ltd., Espoo, pp. 89-93. 
H1 Patents 
2010 
Yli-Kauhaluoma, J, Koskimies, S, Alakurtti, SA, Bergström, P, Mäkelä, T, Vuorela, P, Tammela, P, Minkkinen, J, Pohjala, L Nov. 30 
2010, Betuliiniperäiset yhdisteet antimikrobisina aineina, 121468. 
Yli-Kauhaluoma, J, Pitkänen, P, Heiskanen, N, Wähälä, K, Hulkko, J, Koskimies, S Jan. 29 2010, Menetelmä oligo-/polyestereiden 
valmistamiseksi suberiinin ja/tai kutiinin karboksyylihapposeoksesta, FI-120684. 
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1 Analysis of activities 2005-2010 
 
- Associated person is one of Moshe Finel ,  Erik Wallen ,  Henri Xhaard ,  Jari Yli-Kauhaluoma 
, Ingo Aumuller ,  Kirsi Harju ,  , Paula Kiuru , 
 Liisa Laakkonen , Mohanathas Rajaratnam ,  Leslie Regad , 
 Swapan Kumar Samanta, Andrew Charles Tadd ,  Sami Aleksi Alakurtti , Martti Alkio , 
 Ingo Bichlmaier ,  ,  Gustav Boije af Gennäs ,  Raisa Haavikko 
,  Sanna Kaivosaari ,  Leena Keurulainen , Alexandros Kiriazis , 
 Mika Kurkela ,  Tuomo Kaarlo Erik Leikoski ,  Nenad Manevski , 
 Kristian Meinander ,  Antti Siiskonen ,  Nina Sneitz ,  
Taina Sten ,  Michal Andezej Stepniewski ,  Mikko Vahermo ,  Gloria Wissel , 
 Hongbo Zhang ,  Yuezhou Zhang , 
 
Activity type Count 
Supervisor or co-supervisor of doctoral thesis 33 
Prizes and awards 3 
Editor of research journal 1 
Peer review of manuscripts 28 
Editor of special theme number 1 
Assessment of candidates for academic posts 3 
Membership or other role in review committee 12 
Membership or other role in research network 7 
Membership or other role in national/international committee, council, board 19 
Membership or other role in public Finnish or international organization 4 
Participation in interview for written media 9 
Participation in TV programme 1 
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2 Listing of activities 2005-2010 
Supervisor or co-supervisor of doctoral thesis 
Moshe Finel ,  
Co-supervisor of Ph.D. research, Moshe Finel, 2000  2006, Finland 
Co-supervisor of PhD research, Moshe Finel, 2004  2009, Finland 
Co-supervisor of Ph.D. research, Moshe Finel, 2005  2008 
Co-supervisor of Ph.D. research, Moshe Finel, 2005  2007 
Supervisor of Ph.D. research, Moshe Finel, 2005  2010 
Supervisor of Ph.D. research, Moshe Finel, 2005  2010 
Co-supervisor of Ph.D. research, Moshe Finel, 2006  2009 
Supervisor of Ph.D. rersearch, Moshe Finel, 2007  2011 
Erik Wallen ,  
Main supervisor of doctoral thesis of Elina M. Jarho, completed in Feb. 2007, Erik Wallen, 2000  2007, Finland 
Main supervisor of doctoral thesis of Päivi H. Kiviranta, completed in Dec. 2008, Erik Wallen, 2003  2008, Finland 
Main supervisor of doctoral thesis of Kristian Meinander, not yet completed, Erik Wallen, 2007  …, Finland 
Henri Xhaard ,  
Co-supervision of Doctoral thesis, Henri Xhaard, 2009  … 
Co-supervision of Doctoral thesis, Henri Xhaard, 2010  … 
Supervision of Doctoral thesis, Henri Xhaard, 2010  … 
Supervision of Doctoral thesis, Henri Xhaard, 2010  … 
Supervision of doctoral thesis, Henri Xhaard, 2010  … 
Jari Yli-Kauhaluoma ,  
Supervisor: Carbon-carbon Bond Formation on Solid Phase, Jari Yli-Kauhaluoma, 01.03.2000  …, Finland 
Supervisor: Dependence of Enzymatic Glucuronidation of Phenolic Compounds on Their p<em>K</em>a Values: A Basic Approach for 
the Design of Inhibitors for the UDP-Glucuronosyltransferase Isoenzyme UGT1A9, Jari Yli-Kauhaluoma, 2002  2005, Germany 
Supervisor: Polymer-supported Diels-Alder Reactions and Pim Kinases, Jari Yli-Kauhaluoma, 01.06.2002  …, Finland 
Supervisor: Synthesis of 1,2,3-Triazoles by the Reaction Between Azides and Enamines, Jari Yli-Kauhaluoma, 2003  2007, Finland 
Supervisor: Design and Synthesis of Protein Kinase C and Anaplastic Lymphoma Kinase Inhibitors, Jari Yli-Kauhaluoma, 01.03.2004  
…, Finland 
Supervisor: Medicinal Chemistry of Birch Triterpenes, Jari Yli-Kauhaluoma, 08.03.2004  …, Finland 
Supervisor: Microchip-Based Combinatorial Chemistry, Jari Yli-Kauhaluoma, 01.08.2004  …, Finland 
Supervisor: Synthesis of Metabolites of Psychostimulants, Antiœstrogens, Aromatase Inhibitors and -blockers, Jari Yli-Kauhaluoma, 
01.01.2004  …, Finland 
Supervisor: Design and Synthesis of Compounds against <em>Chlamydia pneumoniae</em>, Jari Yli-Kauhaluoma, 01.01.2006  …, 
Finland 
Supervisor: Selective Inhibitors of the Human UDP-glucuronosyltransferases, Jari Yli-Kauhaluoma, 01.11.2007  …, Finland 
Supervisor: Antibiotics against <em>Chlamydia pneumoniae</em>, Jari Yli-Kauhaluoma, 01.03.2008  …, Finland 
Supervisor: Purification of Pharmaceuticals and Nutraceutical Compounds by Sub- and Supercritical Chromatography and Extraction, 
Jari Yli-Kauhaluoma, 08.02.2008, Finland 
Supervisor: Stereochemical and Steric Control of Enzymatic Glucuronidation. A Rational Approach for the Design of Novel Inhibitors for 
the Human UDP-Glucuronosyltransferase 2B7, Jari Yli-Kauhaluoma, 22.02.2008, Finland 
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Supervisor: Synthesis of Nitrogen-Containing, Five-Membered Heterocycles. 1,3-Dipolar Cycloadditions, Solid-Phase Techniques, and 
Parallel Methods, Jari Yli-Kauhaluoma, 30.10.2009, Finland 
Supervisor: Terpene Synthases, Jari Yli-Kauhaluoma, 01.05.2009  …, Finland 
Supervisor: Triterpene Derivatives against Trypanosomatidae, Jari Yli-Kauhaluoma, 01.03.2010  …, Finland 
Paula Kiuru ,  
Supervisor: Antibiotics against Chlamydia pneumoniae, Paula Kiuru, 01.03.2008  …, Finland 
Prizes and awards 
Kirsi Harju ,  ,  
Best PhD thesis of the Graduate School in Pharmaceutical Research 2009, Kirsi Harju, 2010, Finland 
Ingo Bichlmaier ,  ,  
Best PhD Thesis of the Graduate School in Pharmaceutical Research 2009, Ingo Bichlmaier, 2009, Finland 
Albert Wuokko Award 2010, Ingo Bichlmaier, 2010 
Editor of research journal 
Jari Yli-Kauhaluoma ,  
Anti-Cancer Agents in Medicinal Chemistry, Jari Yli-Kauhaluoma, 01.01.2009  …, United States 
Peer review of manuscripts 
Moshe Finel ,  
Peer review of many manuscripts, an ongoing activity, Moshe Finel, 01.01.1996  … 
Erik Wallen ,  
Regular peer review of manuscripts, Erik Wallen, 2003  … 
Jari Yli-Kauhaluoma ,  
Peer reviewer: Journal of Chemical Education, Jari Yli-Kauhaluoma, 30.11.2003  …, United States 
Peer reviewer: Chemical Communications, Jari Yli-Kauhaluoma, 14.07.2004  …, United Kingdom 
Peer reviewer: Chemical Society Reviews, Jari Yli-Kauhaluoma, 06.09.2004  …, United Kingdom 
Peer reviewer: Green Chemistry, Jari Yli-Kauhaluoma, 06.01.2004  …, United Kingdom 
Peer reviewer: Journal of Combinatorial Chemistry, Jari Yli-Kauhaluoma, 02.02.2004  …, United States 
Peer reviewer: Organic &amp; Biomolecular Chemistry, Jari Yli-Kauhaluoma, 10.02.2004  …, United Kingdom 
Peer reviewer: The Journal of Organic Chemistry, Jari Yli-Kauhaluoma, 08.07.2004  …, United States 
Peer reviewer: Bioorganic &amp; Medicinal Chemistry Letters, Jari Yli-Kauhaluoma, 21.12.2005  …, United States 
Peer reviewer: Molecular BioSystems, Jari Yli-Kauhaluoma, 08.09.2005, United Kingdom 
Peer reviewer: Tetrahedron, Jari Yli-Kauhaluoma, 13.04.2005  …, United States 
Peer reviewer: Chirality, Jari Yli-Kauhaluoma, 06.07.2006, United States 
Peer reviewer: European Journal of Medicinal Chemistry, Jari Yli-Kauhaluoma, 07.11.2006, Netherlands 
Peer reviewer: European Journal of Pharmaceutical Sciences, Jari Yli-Kauhaluoma, 14.09.2006  …, Finland 
Peer reviewer: Journal of Medicinal Chemistry, Jari Yli-Kauhaluoma, 09.02.2006  …, United States 
Peer reviewer: Molecules, Jari Yli-Kauhaluoma, 13.01.2008, Switzerland 
Peer reviewer: Tetrahedron Letters, Jari Yli-Kauhaluoma, 16.06.2008  …, United States 
Peer reviewer: Acta Chimica Slovenica, Jari Yli-Kauhaluoma, 29.12.2009, Slovenia 
Peer reviewer: Bioorganic &amp; Medicinal Chemistry, Jari Yli-Kauhaluoma, 01.01.2009  …, United States 
Peer reviewer: Proceedings of the National Academy of Sciences USA, Jari Yli-Kauhaluoma, 16.12.2009  …, United States 
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Peer reviewer: Anti-Cancer Agents in Medicinal Chemistry, Jari Yli-Kauhaluoma, 17.01.2010  …, United States 
Peer reviewer: British Journal of Pharmacology, Jari Yli-Kauhaluoma, 01.06.2010, United Kingdom 
Peer reviewer: Current Topics in Medicinal Chemistry, Jari Yli-Kauhaluoma, 01.03.2010  …, United States 
Peer reviewer: Journal of the Serbian Chemical Society, Jari Yli-Kauhaluoma, 15.11.2010, Serbia 
Peer reviewer: Synlett, Jari Yli-Kauhaluoma, 02.08.2010, Germany 
Paula Kiuru ,  
Current Topics in Medicinal Chemistry, Paula Kiuru, 01.2010 
Organic &amp; Biomolecular Chemistry, Paula Kiuru, 10.2010 
Editor of special theme number 
Jari Yli-Kauhaluoma ,  
Guest Editor: Current Topics in Medicinal Chemistry, Jari Yli-Kauhaluoma, 2009  2011, United States 
Assessment of candidates for academic posts 
Jari Yli-Kauhaluoma ,  
Associate Professorship in Chemistry, National University of Singapore, Singapore, Jari Yli-Kauhaluoma, 2006, Singapore 
Chair of the professorship evaluation board, Jari Yli-Kauhaluoma, 2009, Finland 
The Lead Research Fellow in Bioorganic Chemistry, University of Tartu, Estonia, Jari Yli-Kauhaluoma, 06.05.2010  14.05.2010, 
Estonia 
Membership or other role in review committee 
Erik Wallen ,  
Evaluation of funding applications, Erik Wallen, 2008  …, Belgium 
Evaluation of grant applications, Erik Wallen, 2010  …, Finland 
Jari Yli-Kauhaluoma ,  
Reviewer of research grant applications (INTAS), Jari Yli-Kauhaluoma, 2003  2006, Belgium 
Reviewer of research grant applications (ETF), Jari Yli-Kauhaluoma, 2004  2006, Estonia 
Reviewer for the positions of postdoctoral researchers (UHEL), Jari Yli-Kauhaluoma, 2006, Finland 
Reviewer of research grant application (NSF), Jari Yli-Kauhaluoma, 2006  2007, United States 
Reviewer of research grant applications (MATINE), Jari Yli-Kauhaluoma, 2006  2013, Finland 
Reviewer of research grant applications (A*STAR), Jari Yli-Kauhaluoma, 2007, Singapore 
Reviewer of research grant applications, Jari Yli-Kauhaluoma, 21.12.2009  20.01.2010, Denmark 
Reviewer of research grant applications (GACR), Jari Yli-Kauhaluoma, 2009, Czech Republic 
Reviewer of research grant applications, Jari Yli-Kauhaluoma, 30.09.2010  20.10.2010, Serbia 
Paula Kiuru ,  
Reviewer of research grant applications, Paula Kiuru, 2005, Czech Republic 
Membership or other role in research network 
Jari Yli-Kauhaluoma ,  
Head of the Design and Synthesis Group, Viikki Drug Discovery Technology Center (DDTC), Jari Yli-Kauhaluoma, 01.09.2000  
30.06.2005, Finland 
Viikki Research Groups in Biosciences, Jari Yli-Kauhaluoma, 01.09.2000  …, Finland 
Member of the Project Coordination Committee of the FP6 Project: Protein Kinases - Novel Drug Targets for Post Genomic Era (LSHB-
CT-2004-503467), Jari Yli-Kauhaluoma, 01.03.2004  31.08.2009, Finland 
Member of the Management Committee of the COST Programme CM0801, Jari Yli-Kauhaluoma, 18.06.2008  27.11.2012, Finland 
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Vice co-ordinator of the FP7 project FORESTSPECS, Jari Yli-Kauhaluoma, 01.05.2009  30.04.2012, Finland 
Member of the Board of the Paul Ehrlich MedChem Euro-PhD Network, Jari Yli-Kauhaluoma, 01.01.2010  31.12.2013, Finland 
Vice co-ordinator of the FP7 project MAREX, Jari Yli-Kauhaluoma, 01.08.2010  31.07.2014, Finland 
Membership or other role in national/international committee, council, board 
Erik Wallen ,  
Executive committee member of the Finnish Pharmaceutical Society, Erik Wallen, 2009  …, Finland 
Finnish delegate in the council of the European Federation for Medicinal Chemistry (EFMC), Erik Wallen, 2010  … 
Jari Yli-Kauhaluoma ,  
Member of the American Chemical Society, Jari Yli-Kauhaluoma, 1992  …, United States 
Member of the Sigma Xi, The Scientific Research Society, Jari Yli-Kauhaluoma, 1998  …, United States 
Member of the management group of the Viikki Drug Discovery Technology Center (DDTC), Jari Yli-Kauhaluoma, 01.09.2000  
30.06.2005, Finland 
Co-ordinator of the Drug Discovery Research Programme of the Biocenter Viikki Research Group Organization, Jari Yli-Kauhaluoma, 
01.01.2001  31.12.2008, Finland 
Deputy Member of the Faculty Council, Faculty of Pharmacy, University of Helsinki, Jari Yli-Kauhaluoma, 01.01.2004  31.12.2009, 
Finland 
Deputy Member of the Research Committee, Faculty of Pharmacy, University of Helsinki, Jari Yli-Kauhaluoma, 01.01.2004  
31.12.2009, Finland 
Member of the Board of the Drug Discovery Technology Center (DDTC) of the University of Helsinki, Jari Yli-Kauhaluoma, 01.01.2005 
 31.12.2005, Finland 
Member of the Chemical Committee of the University of Helsinki, Jari Yli-Kauhaluoma, 2005  2010, Finland 
CBRN Division of the Scientific Advisory Board for Defence (MATINE), Jari Yli-Kauhaluoma, 17.05.2006  31.12.2013, Finland 
Chair of the Admissions Committee, Faculty of Pharmacy, University of Helsinki, Jari Yli-Kauhaluoma, 01.01.2007  31.12.2009, 
Finland 
Member of the Board of the Viikki Science Library of the University of Helsinki, Jari Yli-Kauhaluoma, 01.01.2007  31.12.2009, Finland 
Pharmacopoeia Committee of the National Agency of Medicines, Jari Yli-Kauhaluoma, 01.03.2008  26.10.2009, Finland 
Member of the Board: Paul Ehrlic European Medicinal Chemistry Ph.D. Network (Euro-PhD), Jari Yli-Kauhaluoma, 01.08.2009  …, 
Finland 
Chair of the Research Committee, Faculty of Pharmacy, University of Helsinki, Jari Yli-Kauhaluoma, 01.01.2010  31.07.2010, Finland 
Member of the Faculty Council, Faculty of Pharmacy, University of Helsinki, Jari Yli-Kauhaluoma, 01.01.2010  31.12.2013 
Member of the Steering Group of the ChemistryLab Gadolin, Jari Yli-Kauhaluoma, 2010  …, Finland 
Pharmacopoeia Committee of the Finnish Medicines Agency, Jari Yli-Kauhaluoma, 01.01.2010  28.02.2013, Finland 
Membership or other role in public Finnish or international organization 
Jari Yli-Kauhaluoma ,  
Chief research scientist: Technical Research Centre of Finland (VTT), Jari Yli-Kauhaluoma, 01.01.2001  …, Finland 
Vice-dean of the Faculty of Pharmacy in charge of research and doctoral training, Jari Yli-Kauhaluoma, 01.01.2010  31.07.2010, 
Finland 
Vice-director of the Graduate School in Pharmaceutical Research, Jari Yli-Kauhaluoma, 01.01.2010  31.12.2011, Finland 
Paula Kiuru ,  
Board member, Paula Kiuru, 2010  …, Finland 
Participation in interview for written media 
Jari Yli-Kauhaluoma ,  
Mediauutiset-lehti, Jari Yli-Kauhaluoma, 07.10.2005  31.12.2011, Finland 
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Tuohesta voi tulla lääke, Jari Yli-Kauhaluoma, 07.10.2005, Finland 
Työvoimatilanne ja proviisoriopiskelijoiden sisäänottomäärät: Mikä on oikea tasapaino?, Jari Yli-Kauhaluoma, 2007  …, Finland 
Kemiaa mitalin kääntöpuolelta, Jari Yli-Kauhaluoma, 22.08.2008, Finland 
Healing waste from a pulp mill, Jari Yli-Kauhaluoma, 2009, Finland 
Lääkekemia imaisi pikku kemistin, Jari Yli-Kauhaluoma, 28.08.2009, Finland 
Tonneittain tuohta, Jari Yli-Kauhaluoma, 18.06.2009, Finland 
Apteekkikokemusta metsästämässä, Jari Yli-Kauhaluoma, 2010, Finland 
Metyleenidioksipyrovaleroni, Jari Yli-Kauhaluoma, 2010, Finland 
Participation in TV programme 
Jari Yli-Kauhaluoma ,  
Koivunkuoresta apua alkueläintauteihin?, Jari Yli-Kauhaluoma, 01.07.2009, Finland 
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Web of Science(WoS)-based bibliometrics of the RC’s publications data 1.1.2005-31.12.2010  
by CWTS, Leiden University, the Netherlands 
Research Group: Yli-Kauhaluoma J 
Basic statistics 
Number of publications (P) 125 
Number of citations (TCS) 657 
Number of citations per publication (MCS)   5.29 
Percentage of uncited publications 23% 
Field-normalized number of citations per publication (MNCS)    .91 
Field-normalized average journal impact (MNJS)   1.24 
Field-normalized proportion highly cited publications (top 10%)    .68 
Internal coverage    .89 
 
Trend analyses 
 
MNCS 
 
THCP10 
 
MNJS 
Collaboration 
 
Performance (MNCS) by collaboration type 
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Web of Science(WoS)-based bibliometrics of the RC’s publications data 1.1.2005-31.12.2010  
by CWTS, Leiden University, the Netherlands 
Research profile 
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